Clinical trial register · European Union · CTIS

EU Clinical Trials Tracker

Name: EU clinical trials authorised under CTIS
Creator: Priya Life Science
License: https://www.ema.europa.eu/en/about-us/legal-notice

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2557 most recently authorised of 12788 total CTIS records — a stated recency window, not the full historical archive. Synced 07 Nov 2026, 03:17 UTC

2557

Shown in this register

most recently authorised

12,788

Total on CTIS

full historical archive

789

Phase III

within the shown window

Top member states

Spain 1074 France 933 Germany 893 Italy 777 Poland 614 Netherlands 544

Narrow the registerReset

Search within results

Phase

Lead sponsor

Member state

All 28 states

Trials in this register

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase III

A Double-blind, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium on Normalization of Alkaline Phosphatase Levels in Patients with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)

2026-526680-38-00Primary Biliary Cholangitis (PBC)

DrugSaroglitazar Magnesium

Zydus Therapeutics Inc.

Digestive System Diseases

Greece, Italy, Czechia

06/11/2026

Phase III

A Phase 3, Open-label Study of Ivonescimab Versus Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Experienced Disease Progression Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (HARMONi-10)

2026-526300-67-00Locally Advanced, Unresectable Non-Small Cell Lung Cancer (…

DrugsIvonescimab·Durvalumab

Summit Therapeutics Inc.

Neoplasms

Greece, Germany, France

06/11/2026

Phase III

A Phase III, Randomized, Open label Study of Izalontamab Brengitecan (Iza-bren/BMS-986507/BL-B01D1) in Combination with Osimertinib versus Osimertinib Monotherapy or Osimertinib in combination with Platinum-based Chemotherapy as First-Line Therapy in Patients with EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

2026-526486-21-00EGFR-Mutant Locally Advanced or Metastatic Non-small Cell L…

DrugsPegfilgrastim·Iza-bren·Osimertinib·Pemetrexed

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Germany

06/11/2026

Phase III

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris

2025-524656-56-01Lichen Planopilaris

DrugBrepocitinib

Priovant Therapeutics Inc.

Skin and Connective Tissue Diseases

Belgium, Netherlands, France, Italy

06/11/2026

Phase III

UNLOAD-CHF Urea for Normalizing hyponatremia and reducing voLume Overload in Acute and Chronic Heart Failure

2025-523981-26-03Chronic heart failure and Hyponatremia

Nutricion Medica S.L.

Cardiovascular Diseases

Spain

05/11/2026

Phase III

A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL‑M07D1) vs. Platinum-based Chemotherapy in Patients with HER2‑expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy

2026-527617-29-00Urothelial carcinoma metastatic

DrugsGemcitabine·Cisplatin

Systimmune Inc.

Neoplasms

Germany, Bulgaria, France, Hungary, Italy

05/11/2026

Phase III

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

2026-526437-25-00Cutaneous Sarcoidosis

DrugBrepocitinib

Priovant Therapeutics Inc.

Skin and Connective Tissue Diseases

Germany, Spain, Italy, France

04/11/2026

Phase III

DECEMBER: De Escalation of CDK4/6 inhibitors for ER+ HER2- Metastatic BrEast Cancer in complete Response

2026-526319-12-00HER2-negative metastatic or locoregional breast cancer

DrugsRibociclib·Abemaciclib·Palbociclib

Unicancer

Neoplasms

France

04/11/2026

Phase III

Phase III, double blind, placebo controlled, clinical trial to evaluate the efficacy and safety of Depigoid Olea europaea (1000 DPP/mL), a depigmented polymerised allergen extract of olive pollen, compared with placebo in patients with moderate to severe allergic rhinoconjunctivitis with or without asthma due to olive pollen allergy.

2026-525840-13-00Moderate to severe allergic rhinoconjunctivitis, with or wi…

LETI Pharma S.L.U.

Immune System Diseases

Portugal, Spain

04/11/2026

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

2025-525022-35-00Moderate-to-Severe Atopic Dermatitis

Hunan Mabgeek Biotech Co. Ltd.

Skin and Connective Tissue Diseases

Czechia, Spain

04/11/2026

Phase III

Assessment of self-perceived stress and repetitive behaviors after six weeks of daily intranasal oxytocin administration versus placebo: a randomised, multicentre, parallel group pragmatic trial in 210 men and women with autism

2025-524797-42-00Autism Spectrum Disorder

DrugOxytocin

UZ Leuven

Mental Disorders

Belgium

03/11/2026

Phase III

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age with Moderate-to-Severe Atopic Dermatitis (ZENITH AD-1)

2025-524925-42-00Atopic Dermatitis

DrugRezpegaldesleukin

Nektar Therapeutics

Skin and Connective Tissue Diseases

Lithuania, Slovakia, Bulgaria, Greece, Czechia, Spain, Belgium

03/11/2026

Phase III

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age with Moderate-to-Severe Atopic Dermatitis

2025-525129-11-00Atopic Dermatitis

DrugRezpegaldesleukin

Nektar Therapeutics

Immune System Diseases

Portugal, Latvia, Italy, Czechia, Hungary, Croatia

03/11/2026

Phase III

A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM 201 in Naïve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD)

2025-523820-26-01Growth Hormone Deficiency (GHD)

Lumos Pharma LLC

Hormonal diseases

Italy, France, Spain

30/10/2026

Phase III

A Phase 3 extension study to investigate long-term safety and tolerability of frexalimab in participants with multiple sclerosis.

2026-525688-41-00multiple sclerosis

DrugsTeriflunomide·Frexalimab

Sanofi-Aventis Recherche & Developpement

Nervous System Diseases

Hungary, Belgium, Lithuania, Spain, France, Germany, Netherlands, Poland, Denmark, Slovakia, Italy, Austria, Bulgaria, Portugal, Greece, Czechia, Sweden

30/10/2026

Phase III

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis

2026-526538-15-00Rheumatoid arthritis

DrugsFolic Acid·Hydrocortisone·Ibuprofen·Infliximab

Celltrion Inc.

Musculoskeletal Diseases

Poland

30/10/2026

Phase III

Finnish Dexamethasone Trial for Chronic Subdural Hematoma (FINDEX): A Multicenter, Double-Blind, Placebo-Controlled Randomized Controlled Trial

2026-527048-41-00Chronic subdural hematoma

HUS-yhtymae

Nervous System Diseases

Finland

30/10/2026

Phase III

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended- Release Tablets for the Treatment of Chronic Cough in Participants with Idiopathic Pulmonary Fibrosis (IPF) (OCEAN-1)

2026-525877-38-00Chronic Cough

DrugNalbuphine

Trevi Therapeutics Inc.

Respiratory Tract Diseases

Spain, Poland

28/10/2026

Phase III

A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bevacizumab Compared with Platinum Doublet with Bevacizumab in Participants with Platinum-Sensitive Ovarian Cancer

2025-523366-24-00Ovarian Neoplasms

DrugsDoxorubicin·Gemcitabine·Paclitaxel·Bevacizumab

Glaxosmithkline Research & Development Limited

Neoplasms

Czechia, Poland, Austria, Italy, Spain, Sweden, Germany, France, Netherlands, Portugal, Finland, Greece

27/10/2026

Phase III

Efficacy and safety of zenagamtide s.c. once weekly compared to placebo in participants with type 2 diabetes and chronic kidney disease inadequately controlled on once daily basal insulin alone or in combination with metformin, SGLT2i, or both (AMBITION 2)

2026-525471-13-00Participants with type 2 diabetes and chronic kidney disease

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Czechia, Germany, Poland

27/10/2026

Phase III

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

2024-518933-28-01Study 1:Endocrine-resistant, HR-positive, HER2-negative, ad…

DrugsGedatolisib·Ribociclib·Palbociclib·Fulvestrant

Celcuity Inc.

Neoplasms

Finland, Bulgaria, Portugal, Germany, Greece, Romania, Poland, Hungary, Czechia, Italy, Denmark, Belgium, France, Spain

27/10/2026

Phase III

AFTER - Treatment of women with Acne vulgaris - Evaluation of the eFficacy of isoTretinoin low-dose vs spironolactonE in the attack phase and spiRonolactone in the maintenance phase: A 2-step randomized controlled trial

2025-520773-39-00acne in adult women

DrugsAdapalene·Tretinoin·Isotretinoin·Spironolactone

Assistance Publique Hopitaux De Paris

Skin and Connective Tissue Diseases

France

26/10/2026

Phase III

A Randomised, Double‑Blind, Placebo‑Controlled, 2‑Cohort, Phase III Study of Saruparib Combined with Physician’s Choice of Androgen Receptor Pathway Inhibitor in Patients With Metastatic Hormone‑Sensitive Prostate Cancer, Previously Treated With Docetaxel or PSMA‑directed 177Lutetium‑Containing Therapy Without Disease Progression, and With Prostate‑Specific Antigen ≥ 0.2 ng/mL: EvoPAR Prostate‑05

2026-526275-38-00Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

DrugsLeuprorelin acetate·Relugolix·Degarelix·Saruparib

AstraZeneca AB

Male Urogenital Diseases

Poland, Hungary, France, Austria, Germany, Spain, Italy

26/10/2026

Phase III

B7981110 A Phase 3, randomized, double blind, placebo controlled study to investigate the safety and efficacy of ritlecitinib in adult and adolescent participants 12 years of age and older with moderate alopecia areata

2026-526355-62-00Moderate alopecia areata (AA)

Pfizer Inc.

Immune System Diseases

Poland, France

26/10/2026

Phase III

Efficacy and safety of zenagamtide s.c. once weekly compared to placebo in participants with type 2 diabetes inadequately controlled on diet and exercise (AMBITION 1)

2026-525470-18-00Participants with type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Poland, Romania, Slovakia

26/10/2026

Phase III

Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG-2

2026-525759-96-00Acute Myeloid Leukemia

DrugsMidostaurin·Quizartinib·Daunorubicin·Cytarabine

Centre Hospitalier Universitaire De Toulouse

Hemic and Lymphatic Diseases

France

23/10/2026

Phase III

TACITE : Impact of maintaining tacrolimus after renal transplant failure on access to a retransplantation, a randomized controlled trial

2025-523386-26-00renal transplant failure

DrugTacrolimus

University Hospital Of Clermont-Ferrand

Immune system processes

France

23/10/2026

Phase III

A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-360 in Participants with Selected Central Hypersomnia Conditions

2025-522833-68-01Central Hypersomnia Conditions

Takeda Development Center Americas Inc.

Nervous System Diseases

Spain, France, Italy

23/10/2026

Phase III

MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO EVALUATE EFFICACY AND SAFETY OF CLR-07-23 (HEPARAN SULFATE 120 MG PROLONGED-RELEASE TABLETS) IN THE TREATMENT OF PRIMARY CHRONIC VENOUS DISEASE.

2024-514679-16-00PRIMARY CHRONIC VENOUS DISEASE OF THE LOWER LIMBS

Farmaceutici Damor S.p.A.

Cardiovascular Diseases

Italy

23/10/2026

Phase III

A randomised, multi-center, double-blind, sham-controlled, parallel-group, phase III clinical study to evaluate the efficacy and safety of intrathecally administered rugonersen in pediatric and adult participants with Angelman syndrome.

2025-523729-16-00Angelman syndrome

Ohb Pediatrics Limited

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Poland, Germany, Netherlands, Italy

23/10/2026

Phase III

Efficacy and safety of zenagamtide s.c. once weekly compared to semaglutide s.c. once weekly at higher dose levels in participants with type 2 diabetes inadequately controlled on metformin, SGLT2i, or both (AMBITION 3)

2026-525472-26-00Participants with type 2 diabetes

DrugSemaglutide

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Portugal, Bulgaria, Germany, Croatia, Hungary, Czechia, Romania, Spain, Italy, Denmark, Slovakia, Greece, Poland

23/10/2026

Phase III

A Phase 3, Global, Multi-center, Double-blind, Randomized Study of ASP2138 plus Chemotherapy (CAPOX or mFOLFOX6) with Pembrolizumab vs Placebo plus Chemotherapy with or without Pembrolizumab in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in Participants Whose Tumors Are HER2-negative and Claudin (CLDN) 18.2-positive

2025-524557-14-00Locally Advanced Unresectable or Metastatic Gastric or Gast…

DrugsASP2138·Capecitabine·Oxaliplatin·Pembrolizumab

Astellas Pharma Global Development Inc.

Neoplasms

Poland, Romania, Spain, Belgium, Czechia, Portugal, Italy, Germany, France

23/10/2026

Phase III

A 52-week multi-center, randomized, double-blind, placebo- controlled phase 3 study to evaluate the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO)

2025-524497-41-00Chronic Pruritus of Unknown Origin (CPUO)

DrugsPimecrolimus·Remibrutinib·Tacrolimus

Novartis Pharma AG

Immune System Diseases

Germany, Austria, Poland, Spain, Italy, France

23/10/2026

Phase III

Efficacy and safety of zenagamtide s.c. once weekly compared to semaglutide s.c. once weekly at lower dose levels in participants with type 2 diabetes inadequately controlled on metformin, SGLT2i, or both (AMBITION 4)

2026-525474-20-00Participants with type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Croatia, Spain, Portugal, Hungary, Bulgaria, Poland

21/10/2026

Phase III

A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing interstitial lung disease at risk for disease progression (FIBRONEER-ACT)

2026-526028-38-00Interstitial lung diseases

DrugNerandomilast

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Respiratory Tract Diseases

Belgium, France, Netherlands, Finland, Italy, Spain, Germany, Poland, Austria

21/10/2026

Phase III

A Phase 3 Double-blind, Placebo-controlled Randomized Withdrawal Maintenance Trial of KarXT Treatment in Participants with Schizophrenia

2025-523664-20-00Esquizofrenia, Schizophrenia

DrugKarXT

Bristol-Myers Squibb Services Unlimited Company

Mental Disorders

Romania, Bulgaria, Poland, Denmark, Spain

20/10/2026

Phase III

ROSY-S: Rollover Study for Participants Who have Completed a Previous Study with Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Beneﬁt From Continued Treatment

2026-526419-13-00Systemic Sclerosis Cutaneous Lupus Erythematosus Myopathies…

DrugAnifrolumab

AstraZeneca AB

Musculoskeletal Diseases

Netherlands, Belgium, Bulgaria, Romania, Italy, Germany, Austria, Spain, Portugal, Greece, Czechia, Poland, France

20/10/2026

Phase III

A 2-year, single-arm, multi-center study to explore the efficacy and safety of pegcetacoplan in preventing disease recurrence in adolescent and adult kidney transplant recipients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis

2026-526392-39-00Male or female patients with a diagnosis of C3G or primary …

DrugPegcetacoplan

Swedish Orphan Biovitrum AB (publ)

Immune System Diseases

Italy, Finland, France, Germany, Spain

20/10/2026

Phase III

A Phase 3 Open-Label, Randomized, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects

2026-525656-28-00Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) /…

DrugsRocbrutinib·Pirtobrutinib

Newave Pharmaceutical Inc.

Hemic and Lymphatic Diseases

Poland, Germany, Spain, Czechia, Italy, France

20/10/2026

Phase III

DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”

2026-525268-16-00Non Small Cell Lung Cancer

DrugsTepotinib·Capmatinib·Brigatinib·Adagrasib

Universita' Degli Studi Di Torino

Neoplasms

Italy

19/10/2026

Phase III

A Randomized Phase 2/3, Double-blind, Placebo Controlled Adaptive Study Evaluating the Efficacy and Safety of Momelotinib in Participants with VEXAS Syndrome

2025-524416-11-00VEXAS Syndrome

Glaxosmithkline Research & Development Limited

Immune System Diseases

France, Belgium, Italy, Spain, Austria, Germany, Netherlands, Portugal, Poland, Greece

19/10/2026

Phase III

A Randomized, Open-label, Phase 3 Trial of Petosemtamab in Combination With mFOLFOX6 or FOLFIRI Versus Cetuximab in Combination With mFOLFOX6 or FOLFIRI as First-line Treatment for Participants With RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

2026-525883-17-00Colorectal Cancer

DrugsPetosemtamab·Erbitux·Fluorouracil·Irinotecan

Genmab A/S

Neoplasms

Italy, Poland, Greece, France, Spain, Austria, Bulgaria, Germany, Hungary, Czechia, Netherlands, Belgium, Romania, Denmark

19/10/2026

Phase III

J2A-MC-GZVA:A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared with Placebo in Individuals with Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

2026-526175-35-00Obesity, Abdominal, Overweight, Prehypertension, Prediabeti…

DrugOrforglipron

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Czechia, Germany, Spain

19/10/2026

Phase III

A Phase 3, Prospective, Open-label, Multicenter, Single-arm Study to Investigate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Subjects with Secondary Immune Deficiency due to Hematologic Malignancies Treated with B-cell Targeting Chimeric Antigen Receptor T-Cell and T-Cell Redirecting Therapies

2026-525626-38-00Secondary Immune Deficiency

DrugHizentra

CSL Behring LLC

Immune System Diseases

Czechia, Denmark, France, Spain, Italy, Poland, Belgium, Germany

19/10/2026

Phase III

A multinational, open-label study to investigate efficacy and safety of denecimig (Mim8) in adults with acquired haemophilia A

2026-525529-19-00acquired haemophilia A

Novo Nordisk A/S

Hemic and Lymphatic Diseases

France, Italy, Greece, Poland, Spain, Denmark, Germany

19/10/2026

Phase III

A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared with Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease (Stage 3b and 4)

2026-526114-90-00Renal Insufficiency, Chronic

DrugDapagliflozin

AstraZeneca AB

Cardiovascular Diseases

France, Germany, Austria, Poland, Romania, Italy, Greece, Bulgaria, Spain

19/10/2026

Phase III

Standard-dose versus high-dose prophylactic anticoagulation in critically ill medical patients at risk for thromboprophylaxis failure: a multicentre, parallel-group, double-blind, phase III, randomized controlled trial

2025-524864-40-00Intensive care unit (ICU) medical patients with high risk f…

DrugEnoxaparin

Hopital Erasme

Hemic and Lymphatic Diseases

France, Belgium

19/10/2026

Phase III

VISION - Non-Inferiority of videolaryngoscopy-assisted intubation without neuromuscular blockade versus with neuromuscular blockade on first-attempt intubation success free of major complications: a randomized clinical trial

2026-526824-29-00Adult patients requiring elective general anaesthesia with …

DrugAtracurium

Assistance Publique Hopitaux De Paris

Surgical Procedures, Operative

France

16/10/2026

Phase III

Prospective diagnostic performance of PET/CT using the novel fibroblast imaging tracer [18F]-AlF-FAPI-74 versus power doppler ultrasound in psoriasis patients with arthralgia: early detection of psoriatic arthritis

2026-526942-29-00psoriasis and arthralgia

UZ Leuven

Musculoskeletal Diseases

Belgium

16/10/2026

Phase III

Phase III, randomized, double‑blind, multicenter clinical trial to evaluate the efficacy of sildenafil citrate in reducing adverse perinatal events during labour in small‑for‑gestational‑age fetuses

2026-526112-37-00Pregnant individuals with singleton pregnancies between 37.…

Fundacio Sant Joan De Deu

Female Urogenital Diseases and Pregnancy Complications

Spain

16/10/2026

Phase III

Optimizing Postoperative Betablockade with Landiolol on top of oral betablocker to prevent New-Onset Atrial Fibrillation Following Cardiac Surgery in Caucasian patients: A multicenter, randomized, double-blind study.

2025-524518-26-03Patient scheduled for elective cardiac surgery using cardio…

DrugLandiolol

GCS Ramsay Sante Enseignement Et Recherche

Cardiovascular Diseases

France

16/10/2026

Phase III

A Phase 3, Multicenter, Open Label, Basket, Long-term Extension Study of Icotrokinra in Pediatric Clinical Study Participants

2026-526290-41-00Immune System Disorders

DrugIcotrokinra

Janssen Cilag International

Immune System Diseases

Hungary, Spain, Germany, Poland

15/10/2026

Phase III

Optimizing treatment for chronic exertional compartment syndrome of the lower extremities: the Botox study, a double-blind randomized placebo controlled trial.

2025-524042-99-00Chronic exertional compartment syndrome (CECS) of the leg

DrugBotulinum toxin type A

Universitair Medisch Centrum Utrecht

Musculoskeletal Diseases

Netherlands

15/10/2026

Phase III

J3R-MC-YDAS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk

2026-525919-14-00Cardiovascular Diseases, Diabetes Mellitus, Type 2, Overwei…

DrugEloralintide

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Spain, Poland, France, Italy, Germany, Czechia, Romania, Hungary

15/10/2026

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications

2026-527531-33-00Non-immunocompromised participants at higher risk of influe…

Cidara Therapeutics Inc.

Respiratory Tract Diseases

Germany

15/10/2026

Phase III

C5701009 - A Phase 3, Open-label, Randomized Study To Evaluate Enfortumab Vedotin in Combination with Pembrolizumab in Adult participants with Muscle-Invasive Bladder Cancer Who Are Ineligible for or have elected not to undergo cystectomy

2026-525612-34-00Muscle-Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Pembrolizumab

Pfizer Inc.

Female Urogenital Diseases and Pregnancy Complications

France, Spain, Italy, Germany

15/10/2026

Phase III

A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis (stage F4 fibrosis) due to metabolic dysfunction-associated steatohepatitis (NEBULA-2)

2026-525757-37-00Metabolic dysfunction-associated steatohepatitis

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Netherlands, Germany, Austria, France, Spain, Italy, Bulgaria, Poland, Belgium, Greece

13/10/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Huntington’s disease (HD).

2026-526093-16-00Huntington’s disease (HD).

DrugPridopidine

Ferrer Internacional S.A., Prilenia Therapeutics B.V.

Nervous System Diseases

Spain, Italy, Portugal, Poland, France, Netherlands, Germany, Belgium, Czechia

12/10/2026

Phase III

A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (NEBULA-1)

2026-525755-82-00Metabolic dysfunction-associated steatohepatitis

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Netherlands, Greece, Austria, Spain, Italy, France, Belgium, Bulgaria, Germany, Poland

12/10/2026

Phase III

A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients with Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)

2025-524969-24-00Pancreatic Adenocarcinoma

DrugsRMC-9805·Cetuximab·Gemcitabine·Paclitaxel

Revolution Medicines Inc.

Neoplasms

Austria, Netherlands, Germany, Sweden, Spain, Belgium, Norway, France, Italy

12/10/2026

Phase III

A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) versus Docetaxel in Participants with KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum-based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)

2025-524079-22-00KRAS G12D-mutated Locally Advanced (Unresectable) or Metast…

DrugSetidegrasib

Astellas Pharma Global Development Inc.

Neoplasms

Italy, Poland, Spain, France, Belgium, Germany

12/10/2026

Phase III

Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer with a High Tumor Burden (HighFive) [without IMPD-Q]

2026-525497-18-00NSCLC, Non-Small Cell Lung Cancer Stage IV

DrugsPemetrexed·Tislelizumab·Paclitaxel·Cisplatin

AIO-Studien gGmbH

Neoplasms

Germany

12/10/2026

Phase III

An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination with Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1

2026-526026-40-00human immunodeficiency virus type 1 (HIV-1)

DrugsGS-3242·B/F/TAF·Lenacapavir

Gilead Sciences Inc.

Virus Diseases

Portugal, Poland, Germany, Romania, Spain

09/10/2026

Phase III

COTRIM-HIGH - Efficacy of daily prophylaxis with Cotrimoxazole 800/160mg on the occurrence of bacterial infections at six months after renal transplantation

2026-526183-20-00bacterial infection, kidney transplant

DrugTrimethoprim-sulfamethoxazole

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

08/10/2026

Phase III

A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept (TAK‑226) Compared to Placebo in Participants With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy

2026-525660-17-00Myelofibrosis

DrugsElritercept·Ruxolitinib

Takeda Development Center Americas Inc.

Hemic and Lymphatic Diseases

Italy, Austria, Greece, Ireland, Bulgaria, Poland, Sweden, Belgium, Germany, Spain, Czechia, France, Romania, Hungary

08/10/2026

Phase III

IFEM – Pembrolizumab monotherapy versus pembrolizumab in combination with chemotherapy as first line therapy in females with advanced Non-small cell lung cancer (NSCLC) & PD-L1 expression ≥ 50%

2026-525387-18-00Advanced non‑small cell lung cancer (NSCLC)

DrugsPemetrexed·Paclitaxel·Cisplatin·Carboplatin

Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Neoplasms

Germany

08/10/2026

Phase III

Blomia tropicalis allergen extract. Study of the sensitivity and specificity of the prick test diagnostic preparation

2026-525639-18-00Allergy to Blomia tropicalis

Inmunotek S.L.

Immune System Diseases

Spain

08/10/2026

Phase III

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Obesity or Overweight With at Least One Weight Related Comorbidity Without Type 2 Diabetes Mellitus

2025-523379-41-00Obesity or Overweight, Weight-Related Comorbidity, without …

AstraZeneca AB

Nutritional and Metabolic Diseases

Italy, Czechia, Germany, Bulgaria, France, Poland

08/10/2026

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants with Active Primary Sjögren’s Disease

2026-525556-28-00Active Primary Sjögren’s Disease

DrugTelitacicept

Vor Biopharma Inc.

Immune System Diseases

Poland, Spain, Hungary, Italy, Netherlands, Romania, Belgium, France, Bulgaria, Germany

06/10/2026

Phase III

An open-label, single-arm, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients who have completed a clinical trial (parent study) in the iptacopan pediatric program.

2026-525677-39-00Paroxysmal Nocturnal Hemoglobinuria (PNH) and IgA nephropat…

DrugIptacopan

Novartis Pharma AG

Immune System Diseases

Italy

06/10/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Idiopathic Hypersomnia (IH) Followed by an Open-label Extension

2025-523822-42-00Idiopathic hypersomnia (IH)

DrugPitolisant

Harmony Biosciences Management Inc.

Nervous System Diseases

France, Germany, Belgium, Spain, Italy, Poland

06/10/2026

Phase III

A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (TE NDMM) (DURGA-6)

2026-525367-40-00Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Melphalan·Lenalidomide

AstraZeneca AB

Neoplasms

Germany, Spain, Norway, Italy, Denmark, France, Poland

06/10/2026

Phase III

A Randomized, Double-Blind, Placebo-controlled, Safety and Efficacy Study of VI-0106 (Extended-release Tacrolimus) in Subjects with PAH and Functional Limitations Despite Optimized Therapy with Available PAH Medications

2025-524596-24-00Pulmonary Arterial Hypertension (PAH)

DrugTacrolimus

Vivus B.V., Vivus LLC

Respiratory Tract Diseases

Italy, France, Czechia, Poland, Latvia, Germany, Spain

05/10/2026

Phase III

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Type 2 Diabetes Mellitus and Obesity or Overweight

2025-524616-11-00Obesity or overweight Diabetes Mellitus, Type 2

AstraZeneca AB

Nutritional and Metabolic Diseases

Spain, Poland, Slovakia, Germany

05/10/2026

Phase III

A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine with Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older

2026-526221-18-00Influenza, COVID-19

Sanofi Vaccines US Inc.

Virus Diseases

Belgium, Poland, Spain, Portugal, France, Germany

05/10/2026

Phase III

A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin compared with Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients

2026-525642-30-00Hypercholesterolaemia

DrugsAZD0780·Rosuvastatin

AstraZeneca AB

Nutritional and Metabolic Diseases

Germany, Bulgaria, Hungary, Denmark, Poland, Spain

05/10/2026

Phase III

A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC)

2025-524067-20-00Primary Biliary Cholangitis (PBC)

DrugSaroglitazar Magnesium

Zydus Therapeutics Inc.

Digestive System Diseases

Ireland, Greece, Estonia, Netherlands, Bulgaria, Slovakia, Poland, Latvia, Croatia, Spain, France, Italy

05/10/2026

Phase III

A randomized, double-blind, placebo-controlled, 2-arm multicenter Phase III study to assess the efficacy and safety of ianalumab in participants with Sjogren's disease with high symptom burden (THALASSA)

2025-522271-29-00Sjögren's disease

DrugsTenofovir Alafenamide·Entecavir·Ianalumab

Novartis Pharma AG

Immune System Diseases

Austria, Portugal, Slovakia, Italy, Poland, Hungary, Spain, Czechia, France, Netherlands, Germany

05/10/2026

Phase III

Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - the PREDICT Study

2026-527337-63-00Bacterial urinary tract infections and bloodstream infectio…

DrugPivmecillinam

Region Hovedstaden

Bacterial Infections and Mycoses

Denmark

05/10/2026

Phase III

A Phase 3b, open-label, multicenter, continued access study for participants transitioning from ViiV  Healthcare‑sponsored or ViiV  Healthcare‑collaborative parent studies for HIV treatment Appendix : Management of Participants from Parent Study BRIGHTE

2025-522910-21-00HIV infection

DrugFostemsavir

Viiv Healthcare UK Limited

Virus Diseases

Romania

05/10/2026

Phase III

Multicenter and randomised study on atrial fibrillation prevention after cardiac surgery with a 3-way comparison between standard of care, posterior pericardiotomy and a treatment bundle (colchicine, amiodarone and posterior pericardiotomy) (PREV-AF)

2025-523209-14-00Atrial fibrillation

DrugsAmiodarone Hydrochloride·Bisoprolol·Heparin

Clinique Saint Augustin

Cardiovascular Diseases

France

02/10/2026

Phase III

A Randomized, Double-Blind, Phase II Investigator Initiated Trial of Upadacitinib and Short Glucocorticoid Tapering in Giant Cell Arteritis

2025-523199-22-00Giant Cell Arteritis

DrugUpadacitinib

Rheinische Friedrich-Wilhelms-Universitaet Bonn

Immune System Diseases

Germany

02/10/2026

Phase III

Comparing two common administration styles of racemic ketamine with a TCI model for perioperative analgesia in patients undergoing spinal fusion surgery: A prospective, randomized, single center trial with three parallel groups

2026-527990-12-00spinal fusion surgery

DrugKetamine

CHU Saint Pierre

Musculoskeletal Diseases

Belgium

02/10/2026

Phase III

Impact of Semaglutide in Liver Transplant Candidates with Obesity (SOMAL Study): A Prospective Randomized Study.

2026-526953-32-00Arterial hypertension, Type 2 diabetes mellitus, Obesity, D…

DrugSemaglutide

Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

Surgical Procedures, Operative

Spain

02/10/2026

Phase III

A Phase III, Multicenter, Randomized, Controlled, Double-Blind Study Comparing the Efficacy and Safety of High-Dose (4%) versus Standard (2%) Lidocaine Gel for Local Anesthesia in Transurethral Procedures

2026-526288-40-00Placement or exchange of double-J (DJ) ureteral stent

DrugLidocaine

Farco-Pharma GmbH

Female Urogenital Diseases and Pregnancy Complications

Germany

01/10/2026

Phase III

A prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of subcutaneous immunotherapy with polymerized grass pollen extracts in patients with grass pollen–induced allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate asthma

2026-526100-73-00Grass pollen induced moderate-to-severe allergic rhinitis o…

Inmunotek S.L.

Immune System Diseases

Poland, Spain

01/10/2026

Phase III

C3671017 A PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE IN CHILDREN AT HIGH RISK OF RSV DISEASE

2026-525797-19-00Prevention of lower respiratory tract disease caused by res…

DrugVaxzevria

Pfizer Inc.

Respiratory Tract Diseases

Spain, Poland

01/10/2026

Phase III

iSGLT2 in permanent atrial fibrillation, heart failure with preserved ejection fraction and intermediate NT-proBNP values: randomized clinical trial

2026-525968-18-00Atrial Fibrillation, Heart failure

Institut D Investigacio Sanitaria Pere Virgili

Cardiovascular Diseases

Spain

30/09/2026

Phase III

A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of a subcutaneous allergoid preparation of house dust mite allergens (Dermatophagoides pteronyssinus / Dermatophagoides farinae) in patients with moderate to severe allergic rhinitis/rhinoconjunctivitis with or without controlled allergic asthma.

2026-526213-28-00House dust mite allergy

DrugsDesloratadine·Mometasone furoate

Allergopharma GmbH & Co. KG

Immune System Diseases

Spain

30/09/2026

Phase III

A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living with Overweight or Obesity without Diabetes (RISE-1)

2025-524861-26-00Overweight or Obesity Without Diabetes.

DrugOlatorepatide

Regeneron Pharmaceuticals Inc.

Nutritional and Metabolic Diseases

Romania, Poland, Hungary, Germany, Spain

29/09/2026

Phase III

A Phase 3, Randomized, DoubleBlind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)

2026-525265-48-00Pulmonary Arterial Hypertension

DrugTreprostinil Palmitil

Insmed Inc.

Cardiovascular Diseases

Germany, Hungary, Belgium, France, Italy, Sweden, Austria, Poland, Lithuania, Spain, Romania, Greece

29/09/2026

Phase III

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer’s Disease

2025-524314-29-00Cognitively Unimpaired Individuals at Risk for Progression …

DrugTrontinemab

F. Hoffmann-La Roche AG

Nervous System Diseases

Spain, Denmark

29/09/2026

Phase III

A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants with Atrial Fibrillation (ROXI-EVEREST)

2025-521617-97-00Atrial Fibrillation (AF)

DrugsCenvacibart·Apixaban

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Portugal, Germany, Italy, Czechia, Austria, Spain, Belgium, Netherlands, Poland, Sweden, Greece, Latvia, Hungary, Bulgaria, Romania

29/09/2026

Phase III

A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)

2025-521618-25-00Atrial Fibrillation (AF)

DrugsAmrecibart·Cenvacibart

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Spain, Bulgaria, Hungary, Poland, Romania, Sweden, Germany, Italy, Latvia, Netherlands, Portugal

29/09/2026

Phase III

A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)

2025-522954-37-00Peripheral Artery Disease

DrugsAmrecibart·Cenvacibart·Rivaroxaban

Regeneron Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands

29/09/2026

Phase III

Assessing the efficacy of vasculoprotective dapagliflozin treatment in septic shock patients with microcirculatory dysfunction (GLIFLOSHOCK)

2025-524820-23-00Septic chock

DrugDapagliflozin

Les Hopitaux Universitaires De Strasbourg

Not possible to specify

France

28/09/2026

Phase III

A prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of subcutaneous immunotherapy with polymerized olive pollen (Olea europaea) extracts in patients with olive pollen–induced allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate asthma

2026-526390-41-00Moderate-to-severe allergic rhinitis or rhinoconjunctivitis…

Inmunotek S.L.

Immune System Diseases

Spain

28/09/2026

Phase III

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease

2026-526778-18-00Anemia in subjects with sickle cell disease (SCD)

DrugMitapivat

Agios Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Italy, France, Belgium, Ireland

28/09/2026

Phase III

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

2025-522648-42-01• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent …

DrugsAtumelnant·Hydrocortisone

Crinetics Pharmaceuticals Inc.

Not possible to specify

Sweden, Austria, Spain, Poland, Netherlands, Italy, Germany, France

28/09/2026

Phase III

C4931004 - A Phase 3, Randomized Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Catch-Up Vaccination Regimen of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Children and Adolescents

2025-523445-10-00Pneumoccoccal Immunisation

Pfizer Inc.

Bacterial Infections and Mycoses

Poland, Finland

28/09/2026

Phase III

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

2026-526139-20-00Symptomatic genetic and familial dilated cardiomyopathy.

DrugDanicamtiv

Kardigan Inc.

Cardiovascular Diseases

Poland, Sweden, Belgium, France, Spain, Hungary, Denmark, Italy, Netherlands

28/09/2026

Phase III

A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion, and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects with RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

2026-525886-38-00Inherited retinal dystrophy due to dysfunction in the human…

Atsena Therapeutics Inc.

Eye Diseases

Italy, Germany, Spain, Netherlands, France, Belgium

28/09/2026

Phase III

A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)

2026-525298-38-00generalized Myasthenia gravis

DrugClaseprubart

Dianthus Therapeutics Inc.

Immune System Diseases

Czechia, Portugal, Austria, Bulgaria, Germany, France, Latvia, Poland, Italy, Spain, Denmark

28/09/2026

Phase III

SHING-ID: Fractional dose shingles vaccination

2026-526934-16-00Shingles

Leids Universitair Medisch Centrum (LUMC)

Virus Diseases

Netherlands

28/09/2026

Phase III

POst-Therapy ENhanced Thrombocyte Inhibition At Low NIHSS score (POTENTIAL) – A randomized controlled multicenter trial

2026-525681-22-00Secondary prevention after stroke

DrugsAcetylsalicylic acid·Clopidogrel

Technische Universitaet Dresden

Cardiovascular Diseases

Germany

25/09/2026

Phase III

A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study

2026-526648-11-00Neovascular age-related macular degeneration (nAMD)

DrugAflibercept

Shenzhen Oculgen Biomedical Technology Co. Ltd.

Eye Diseases

Latvia, Poland, Czechia, Hungary

24/09/2026

Phase III

A phase 3 randomized, observer-blind, controlled study to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine, in adults 18-64 years of age

2026-526925-17-00Influenza, Human

GlaxoSmithKline Biologicals

Virus Diseases

Belgium, Germany

24/09/2026

Phase III

A phase 3 randomized, observer-blind, controlled study to evaluate the clinical efficacy of an mRNA- based seasonal influenza vaccine in older adults ≥65 years of age

2026-526682-14-00Influenza, Human

GlaxoSmithKline Biologicals

Virus Diseases

Belgium, Germany, Finland, Spain

24/09/2026

Phase III

A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04).

2025-525030-57-00High-risk muscle invasive urothelial carcinoma (MIUC) origi…

DrugsMycophenolate Mofetil·Infliximab·Rilvegostomig·Enfortumab Vedotin

AstraZeneca AB

Neoplasms

Italy, Poland, Spain, France, Germany

23/09/2026

Phase III

LUMIOS - A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy, safety and tolerability of cenerimod in adult patients with systemic lupus erythematosus and active lupus nephritis in combination with background therapy

2025-522984-14-00Systemic lupus erythematosus and active lupus nephritis

DrugCenerimod

Viatris Innovation GmbH

Immune System Diseases

Germany, Spain, Poland, Bulgaria, Romania

23/09/2026

Phase III

J2A-MC-GZGY: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes

2025-524811-35-00Diabetes Mellitus, Type 2

DrugsDulaglutide·Orforglipron

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Italy, Spain, Belgium

22/09/2026

Phase III

A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Face and Neck Atopic Dermatitis

2025-525133-31-00Face and Neck Atopic Dermatitis

DrugLebrikizumab

Almirall S.A.

Skin and Connective Tissue Diseases

Poland, Germany, Portugal, France, Spain, Denmark

22/09/2026

Phase III

A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight

2026-525408-82-00Chronic Weight Management

Amgen Inc.

Nutritional and Metabolic Diseases

Czechia, Spain, Poland, Denmark, Germany, Italy, Belgium, Finland

21/09/2026

Phase III

A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus

2025-524788-19-00Chronic Weight Management

DrugMaridebart cafraglutide

Amgen Inc.

Nutritional and Metabolic Diseases

Germany, Hungary, Czechia, Italy, Poland, Bulgaria

21/09/2026

Phase III

A global phase 3 randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in children with sickle cell disease

2025-524464-38-00Sickle cell disease

Novo Nordisk A/S

Hemic and Lymphatic Diseases

France, Netherlands, Spain, Italy

21/09/2026

Phase III

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants with Obesity or Overweight with at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus

2025-523295-23-00Obesity or Overweight Weight-Related Comorbidity with/witho…

AstraZeneca AB

Nutritional and Metabolic Diseases

Sweden, Denmark

21/09/2026

Phase III

A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy

2025-523362-25-00Neoplasms, Endometrial

DrugsDoxorubicin·Paclitaxel

Glaxosmithkline Research & Development Limited

Neoplasms

Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia

21/09/2026

Phase III

A Randomized Phase 2/3 Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi GU1)

2026-525831-17-00Locally Advanced or Metastatic Urothelial Carcinoma

Summit Therapeutics Inc.

Neoplasms

Spain

21/09/2026

Phase III

A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults with Idiopathic Pulmonary Fibrosis (SURPASS-IPF)

2025-524493-42-00Idiopathic Pulmonary Fibrosis

DrugsDeupirfenidone·Pirfenidone

Puretech Lyt 100 Inc.

Respiratory Tract Diseases

Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands

18/09/2026

Phase III

A Multicentre, Parallel-Group, Observer-Blind, Randomised, Placebo-Controlled, Pivotal Trial Investigating the Safety and Immunogenicity of Group B Streptococcus Vaccine (GBS-NN/NN2) in Pregnant Women and Infants Born to Pregnant Women Vaccinated During Pregnancy

2026-525385-21-00Prevention of Group B streptoccoccus infection

Minervax ApS

Bacterial Infections and Mycoses

Czechia, Belgium, Denmark, Spain

18/09/2026

Phase III

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

2025-524202-15-00Recurrent Platinum-Sensitive Ovarian Cancer

DrugsPegfilgrastim·Doxorubicin·Paclitaxel·Bevacizumab

Genmab A/S

Neoplasms

Czechia, Netherlands, Lithuania, Ireland, Finland, Hungary, Spain, Greece, Italy, France, Germany, Poland

18/09/2026

Phase III

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily oral ASC30 in Adult Participants with Obesity or Overweight with Weight-Related Comorbidities (AURORA-1)

2026-526172-23-00Obesity or Overweight

Ascletis Pharma (China) Co. Ltd.

Nutritional and Metabolic Diseases

Germany, Greece, Czechia, Poland

18/09/2026

Phase III

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)

2025-524405-33-00Choroidal Melanoma

Aura Biosciences Inc.

Neoplasms

Austria, Netherlands, Belgium, Czechia, Spain, France, Germany, Italy

17/09/2026

Phase III

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)

2026-525617-31-00Metastatic Pancreatic Ductal Adenocarcinoma

DrugsGemcitabine·Paclitaxel

Immuneering Corp.

Neoplasms

Spain, Czechia, Hungary, Belgium, Poland, Germany, France, Italy, Romania

17/09/2026

Phase III

A phase III, randomised, double-blind, placebo-controlled, multicentre trial comparing efficacy and safety of trilaciclib versus placebo in participants with limited-stage small cell lung cancer

2025-525026-35-00Limited-stage small cell lung cancer (LS-SCLC)

Pharmacosmos A/S

Neoplasms

Czechia, Greece, France, Belgium, Italy, Spain, Germany

17/09/2026

Phase III

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants with Obesity or Overweight with Type 2 Diabetes Mellitus (AURORA-2)

2026-526336-39-00Obesity or Overweight with Type 2 Diabetes Mellitus

Ascletis Pharma (China) Co. Ltd.

Nutritional and Metabolic Diseases

Germany, Czechia, Greece, Poland

17/09/2026

Phase III

Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)

2026-525182-53-00Atherosclerotic cardiovascular disease and either overweigh…

Novo Nordisk A/S

Cardiovascular Diseases

Denmark, Czechia, Greece, France, Italy, Germany, Spain, Poland, Netherlands, Bulgaria

16/09/2026

Phase III

A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.

2026-526654-14-01Newly Diagnosed Multiple Myeloma

Janssen Cilag International

Neoplasms

Greece, Portugal, Italy, France, Netherlands, Czechia, Germany, Poland, Spain

16/09/2026

Phase III

A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis

2025-522393-37-00Autoimmune Hepatitis (AIH)

DrugInebilizumab

Amgen Inc.

Digestive System Diseases

Belgium, Germany, Hungary, Czechia, Bulgaria, France, Netherlands, Italy, Poland, Greece, Portugal, Spain

16/09/2026

Phase III

A Phase 3a, observer blind, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational combined measles, mumps, rubella, and varicella vaccine compared with intramuscular administration of ProQuad when administered as a second dose to healthy children aged 15 months to 6 years of age

2025-523274-17-00Measles, mumps, rubella, varicella

GlaxoSmithKline Biologicals

Virus Diseases

Spain, Germany

16/09/2026

Phase III

Randomized double-blinded placebo-controlled study of the efficacy of fluoxetine in add-on treatment of drug-resistant, complex and rare epilepsy in children aged 8 years and older: use of a design evaluating the time to reach a defined number of seizures for each child during the prospective observational phase (FLUOXEPIL)

2024-519897-38-01complex and rare epilepsy in children aged 8 years and older

DrugFluoxetine

Centre Hospitalier Regional De Marseille

Nervous System Diseases

France

15/09/2026

Phase III

An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).

2026-526803-31-00Secondary Antibody Deficiency Associated with Chronic Lymph…

Grifols Therapeutics LLC

Immune System Diseases

Italy, Poland, Czechia, France, Spain

14/09/2026

Phase III

SCARP-DIAL (SGLT2i for CARdiovascular Protection in DIALysis)

2026-526075-35-00Chronic dialysis, Cardiovascular disease

DrugDapagliflozin

Karolinska University Hospital

Reproductive and Urinary Physiological Phenomena

Sweden

10/09/2026

Phase III

C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)

2026-525318-75-00Overweight or Obesity

Pfizer Inc.

Nutritional and Metabolic Diseases

Spain, France, Germany, Poland, Italy

09/09/2026

Phase III

A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)

2026-525489-23-00Relapsed Extensive-Stage Small Cell Lung Cancer After Plat…

Amgen Inc.

Neoplasms

Romania, Poland, Germany, Greece, Netherlands, Hungary, Portugal, France, Belgium, Italy, Spain

08/09/2026

Phase III

A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1

2025-520765-50-00Gaucher Disease Type 1

DrugsSirolimus·Tacrolimus

Spur Therapeutics Limited

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain

08/09/2026

Phase III

EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy

2026-525374-19-00Immune system diseases

DrugImiglucerase

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Hungary, Italy, France, Finland, Germany, Spain

08/09/2026

Phase III

Zoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma

2026-527220-27-00Large B-cell lymphomas, transformations of indolent B-cell …

DrugZoledronic Acid

Region Nordjylland

Neoplasms

Denmark

07/09/2026

Phase III

Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.

2025-523903-31-00Metastatic renal cell carcinoma

DrugsSorafenib·Sunitinib·Axitinib·Cabozantinib

Fondazione IRCCS Istituto Nazionale Dei Tumori

Neoplasms

Italy

03/09/2026

Phase III

A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy

2026-525913-30-00Immune system diseases

DrugsIxazomib·Belumosudil·Imatinib·Sirolimus

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark

02/09/2026

Phase III

A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026).

2025-524606-15-00Type 2 Diabetes mellitus

Tecnimede-Sociedade Tecnico-Medicinal S.A.

Nutritional and Metabolic Diseases

Poland, Germany, Portugal, Italy, Spain

02/09/2026

Phase III

Antibiotikapenetration og vævsrespons ved infektion og rekonstruktiv kirurgi i hoved-hals regionen

2026-526995-22-00Treatment and prevention of post operative infections

DrugsCloxacillin·Cefuroxime·Dicloxacillin·Amoxicillin

Region Midtjylland

Bacterial Infections and Mycoses

Denmark

02/09/2026

Phase III

Effect of GABAergic treatments on cortical plasticity and motor learning capacity in the subacute phase after stroke: a single-case experimental study (GABAPLAST)

2026-526884-39-00Stroke

DrugGabapentin

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

01/09/2026

Phase III

Randomized, controlled, multi-center trial to evaluate the efficacy, tolerability, and safety of an (S)-ibuprofen gel vs. placebo in the local symptomatic and short-term treatment of pain in acute contusions of the soft tissues following blunt trauma

2025-524451-31-00acute contusions of soft tissues

DrugParacetamol

Aponia Laboratories Inc.

Skin and Connective Tissue Diseases

Germany

01/09/2026

Phase III

A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).

2025-524014-29-00Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab

AstraZeneca AB

Neoplasms

Poland, Italy, Denmark, France, Sweden, Germany, Spain

01/09/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

2025-524490-17-00Hereditary Hemorrhagic Telangiectasia (HHT)

DrugEngasertib

Vaderis Therapeutics AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Hungary, Netherlands, Germany, Bulgaria, France, Italy, Lithuania, Spain, Belgium

31/08/2026

Phase III

A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy

2025-523857-32-00Spinal Muscular Atrophy

DrugSalanersen

Biogen Idec Research Limited

Nervous System Diseases

Portugal, Italy, Belgium, Croatia, Hungary, Germany, Ireland, France, Norway, Poland

31/08/2026

Phase III

Evaluation of the Impact of a Strategy of Perioperative NSAID Suppression in Patients Undergoing Video-assisted Thoracic Surgery (VATS) on the Presence of Chronic Postoperative Pain (CPOP): a Randomised Clinical Trial (EVADRAINS)

2025-524917-96-00Thoracic surgery

DrugCalcium

Les Hopitaux Universitaires De Strasbourg

Not possible to specify

France

31/08/2026

Phase III

Targeted versus standard peri-operative prophylaxis in patients colonized with carbapenemase-producing Enterobacterales undergoing liver transplantation: a stepped-wedge cluster randomization trial

2025-523453-34-00Patients colonized with CPE undergoing liver transplantatio…

DrugsEravacycline·Aztreonam·Tigecycline

Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico

Bacterial Infections and Mycoses

Italy

31/08/2026

Phase III

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER

2025-524263-21-01Resected Stage II-III Kirsten rat sarcoma virus oncogene ho…

DrugsDivarasib·Nivolumab·Pembrolizumab

F. Hoffmann-La Roche AG

Neoplasms

France, Spain, Austria, Greece, Portugal, Ireland, Belgium, Italy, Poland, Germany, Netherlands

28/08/2026

Phase III

A multicenter, open-label, single-arm, baseline-controlled trial to assess the efficacy and safety of lucerastat in treatment-naïve/pseudo-naïve adult male participants with Fabry disease

2026-525207-27-00Fabry disease

Idorsia Pharmaceuticals Ltd.

Nutritional and Metabolic Diseases

Germany, France

27/08/2026

Phase III

Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial

2026-525280-40-00Acute ischemic stroke

DrugTenecteplase

Fondation A De Rothschild

Nervous System Diseases

France

25/08/2026

Phase III

A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis

2025-524757-14-00Ocular Myasthenia Gravis

DrugRozanolixizumab

UCB Biopharma

Immune System Diseases

Hungary, France, Greece, Poland, Spain, Italy, Germany

25/08/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension

2025-523821-17-00narcolepsy

DrugPitolisant

Harmony Biosciences Management Inc.

Nervous System Diseases

Belgium, Italy, Germany, France, Spain, Poland

25/08/2026

Phase III

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Etifoxine Monotherapy in The Treatment of Adjustment Disorder with Anxiety (ADWA)

2025-524287-38-00Treatment of adjustment disorder with anxiety (ADWA).

Biocodex

Nervous System Diseases

Bulgaria, France, Romania, Czechia

24/08/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

2025-524928-21-00Pancreatic Adenocarcinoma

DrugRMC-9805

Revolution Medicines Inc.

Neoplasms

Sweden, Spain, France, Poland, Italy, Norway, Belgium, Germany, Czechia, Austria, Netherlands, Denmark

24/08/2026

Phase III

Evaluation of the efficacy and safety of photodynamic therapy with BF-200 ALA (Ameluz®) in immunosuppressed patients with actinic keratoses and superficial basal cell carcinoma at any location.

2026-526649-85-00Immunosuppressed patients with premalignant and malignant s…

Dra. Elena González Guerra

Skin and Connective Tissue Diseases

Spain

24/08/2026

Phase III

A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR

2026-525296-60-00Stargardt Disease (STGD1)

Alkeus Pharmaceuticals Inc.

Eye Diseases

Belgium, France, Spain, Italy, Germany

21/08/2026

Phase III

FOSFOLD - Fosfomycin trometamol compared with another active antibiotic relay therapy for the treatment of acute Escherichia coli pyelonephritis in elderly women: a randomized, multicenter, non-inferiority trial

2025-521663-13-00Women aged 75 years or older presenting with E. coli pyelon…

DrugsCefotaxime·Ertapenem·Aztreonam·Ceftazidime

Assistance Publique Hopitaux De Paris

Female Urogenital Diseases and Pregnancy Complications

France

21/08/2026

Phase III

Surgery versus intra-lesional sclerosis with polidocanol (Aetoxisclerol) in labial venous malformations in children and adults: a randomized controlled trial - SASOV

2025-521374-34-00superficial labial venous malformation

Centre Hospitalier Regional Universitaire De Tours

Cardiovascular Diseases

France

21/08/2026

Phase III

A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate the Efficacy and Safety of Letrozole SIE Compared to Femara® (both in Combination with the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women with HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3)

2025-524846-85-00HR-positive, HER2-negative, inoperable locally advanced o…

DrugsRibociclib·Letrozole

Laboratorios Farmaceuticos Rovi S.A.

Neoplasms

Romania, Spain, Bulgaria, Czechia, Latvia, Poland, Croatia, Slovakia

21/08/2026

Phase III

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

2025-524669-25-00Polycythemia Vera

Deciphera Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Austria, Czechia, Italy, Portugal, Germany, France, Hungary, Spain, Poland

21/08/2026

Phase III

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

2025-524934-24-00Neoplasms, Gastrointestinal Stromal

Glaxosmithkline Research & Development Limited

Neoplasms

Italy, Portugal, Germany, Sweden, Poland, Romania, Finland, Greece, Norway, Spain, Netherlands, France, Hungary

21/08/2026

Phase III

A Multicenter, Randomized, Double-Blind, 2-Treatment Arm Study to Assess Comparative Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Intravenous AVT32-DRL_PB and Keytruda® as an Adjuvant Treatment in Participants with Stage IIB/C-III Melanoma Following Complete Resection

2025-525093-11-00Stage IIB/C-III Melanoma

Alvotech Swiss AG

Neoplasms

Romania, Spain

21/08/2026

Phase III

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Non–Transfusion-Dependent Thalassemia (ENERGIZEKids)

2025-524706-15-00Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Italy, Greece

21/08/2026

Phase III

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

2025-524641-27-00High-Grade Serous Ovarian, Fallopian Tube, or Primary Perit…

K-Group Beta Inc.

Neoplasms

Germany, Spain, Italy, Belgium, Poland, France, Ireland

21/08/2026

Phase III

A 52-week multicenter, randomized, parallel-group trial in overweight people investigating lifestyle changes, mushroom supplementation and bupropion to reduce adiposity and cardiometabolic risk

2026-527136-13-00Overweight or class I obesity (BMI 25.0–34.9 kg/m²), with o…

DrugBupropion

Uppsala University

Nutritional and Metabolic Diseases

Sweden

21/08/2026

Phase III

2025-524707-71-00Transfusion-Dependent Alpha- or Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Italy, Greece

20/08/2026

Phase III

A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

2025-523252-31-00High Risk Smoldering Multiple Myeloma (HR-SMM)

DrugsLinvoseltamab·Daratumumab

Regeneron Pharmaceuticals Inc.

Neoplasms

Italy, Spain, Poland, France, Norway, Greece, Germany

20/08/2026

Phase III

JS2-MC-GZMI: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEW-MDD- 2)

2025-522310-24-00Depressive Disorder, Major

Eli Lilly & Co.

Mental Disorders

Poland, Greece, Spain, Germany

19/08/2026

Phase III

Evaluation of an asPirin-free strategy with ticAgrelor in patieNTs witH a myocardial infarction treatEd medically alONe (PANTHEON)

2025-525159-20-00myocardial infarction

DrugsAcetylsalicylic acid·Ticagrelor

Montreal Heart Institute

Cardiovascular Diseases

France

18/08/2026

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis

2025-524756-54-00Ocular Myasthenia Gravis

DrugRozanolixizumab

UCB Biopharma

Immune System Diseases

Hungary, Greece, Italy, Spain, Germany, Poland, France

18/08/2026

Phase III

Evaluation of the efficacy of intravenous lidocaine on chronic postoperative pain in patients requiring emergency abdominal surgery. Randomized, double-blind, controlled, multicenter study – LIDOC-POPEYE.

2025-523682-24-00emergency abdominal surgery

Centre Hospitalier Universitaire De Nantes

Anesthesia and Analgesia

France

17/08/2026

Phase III

A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration

2025-523500-72-00Neovascular Age-related Macular Degeneration (nAMD)

Amgen Inc.

Eye Diseases

Slovakia, Latvia, Czechia, Poland, Spain, Hungary, Lithuania

17/08/2026

Phase III

Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)

2026-525513-31-00Small-cell lung cancer, limited stage

DrugDurvalumab

Norges Teknisk-Naturvitenskapelige Universitet NTNU

Neoplasms

Denmark, Finland, Estonia, Germany, Lithuania, Sweden, Norway, Netherlands

17/08/2026

Phase III

C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

2025-523447-35-02Pneumoccoccal Immunisation

Pfizer Inc.

Bacterial Infections and Mycoses

Spain, Finland, Poland, Germany, Greece, Hungary, Italy

17/08/2026

Phase III

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

2025-524445-27-00Metastatic castration-resistant prostate cancer (mCRPC)

DrugsBNT324·Prednisone·Docetaxel

BioNTech SE

Male Urogenital Diseases

Belgium, Spain, Italy, Poland, Germany, Hungary

17/08/2026

Phase III

A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared with Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients with Hypercholesterolaemia.

2026-526258-15-00Hypercholesterolaemia

AstraZeneca AB

Nutritional and Metabolic Diseases

Germany

17/08/2026

Phase III

The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI

2026-525898-39-00Advanced hepatocellular carcinoma

DrugsSorafenib·Regorafenib·Tremelimumab·Cabozantinib

Azienda Sanitaria Locale Napoli 1 Centro

Neoplasms

Italy

14/08/2026

Phase III

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP)

2026-525454-11-00Diagnosis of primary ITP according to the 2019 Internationa…

Amgen Inc.

Hemic and Lymphatic Diseases

Spain, Hungary, Germany

14/08/2026

Phase III

Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma [FIRE-12]

2025-524131-39-00locally advanced or metastatic small bowel adenocarcinoma

DrugsCalcium folinate·Irinotecan·Oxaliplatin

Charite Universitaetsmedizin Berlin KöR

Digestive System Diseases

Germany

13/08/2026

Phase III

SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients

2025-523444-12-00Breast Cancer

AstraZeneca AB

Neoplasms

Poland, Spain, France, Germany, Italy

13/08/2026

Phase III

International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies

2025-524676-32-00Patients suffering from rhinitis / rhinoconjunctivitis, wit…

ROXALL Medizin GmbH

Diagnosis

Germany, Spain

12/08/2026

Phase III

Prognostic value assessment of PSMA-T4 examination in the group of patients with triple-negative breast cancer (TNBC) qualified to radical therapy

2025-525110-29-01triple-negative breast cancer

Narodowe Centrum Badan Jadrowych

Neoplasms

Poland

12/08/2026

Phase III

Premedication with dexamethasone for preventing interstitial lung disease in patients with breast cancer treated with trastuzumab deruxtecan

2025-521798-15-00Breast Cancer

DrugDexamethasone

Istituto Di Ricerche Farmacologiche Mario Negri

Neoplasms

Italy

11/08/2026

Phase III

A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study

2024-520387-34-01electrical storm

Fondazione IRCCS Policlinico San Matteo

Cardiovascular Diseases

Italy

11/08/2026

Phase III

AVISO - Assessment of Flecainide versus Bisoprolol as First-Line Treatment for Premature Ventricular Contractions: a Multicenter Randomized Clinical Trial

2025-524584-20-00Premature ventricular contractions (PVC)

DrugsBisoprolol·Flecainide

Assistance Publique Hopitaux De Paris

Cardiovascular Diseases

France

10/08/2026

Phase III

A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)

2025-522824-29-00Primary IgAN

Novartis Pharma AG

Immune system processes

France, Spain

10/08/2026

Phase III

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects with Schizophrenia, Followed by a 40-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

2026-525925-19-00Schizophrenia with negative symptoms

Minerva Neurosciences Inc.

Mental Disorders

Bulgaria, Romania

10/08/2026

Phase III

Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

2025-524626-18-00Overweight and obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden

10/08/2026

Phase III

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs

2025-523333-26-00Graves' Disease (GD)

Argenx

Hormonal diseases

Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria

07/08/2026

Phase III

Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME)

2025-520678-20-00Adult patients with symptomatic and inflammatory Hand osteo…

DrugClobetasol Propionate

Assistance Publique Hopitaux De Paris

Musculoskeletal Diseases

France

07/08/2026

Phase III

BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection

2025-522819-42-01sepsis

DrugsCefotaxime·Ceftazidime·Meropenem·Amoxicillin

Centre Hospitalier Universitaire De Rennes

Bacterial Infections and Mycoses

France

06/08/2026

Phase III

Spironolactone and SGLT2 inhibitor to Address Fontan circulatory failure and Enhance Resilience: The SAFER-Fontan trial

2025-524783-38-00Fontan circulation

UZ Leuven

Cardiovascular Diseases

Belgium

06/08/2026

Phase III

A Phase 3, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents with HIV who are Virologically Suppressed on ART

2024-518511-19-00HIV Infections

Viiv Healthcare UK Limited

Immune System Diseases

Spain

05/08/2026

Phase III

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment

2025-523307-29-00Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hyper…

DrugBenralizumab

AstraZeneca AB

Respiratory Tract Diseases

Denmark, Belgium, France, Italy, Netherlands, Austria, Poland

04/08/2026

Phase III

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)

2025-523935-20-00type 2 diabetes mellitus

AstraZeneca AB

Nutritional and Metabolic Diseases

Poland, Germany, Bulgaria, Czechia

04/08/2026

Phase III

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

2025-523940-12-00type 2 diabetes mellitus

AstraZeneca AB

Nutritional and Metabolic Diseases

Germany, Bulgaria, Spain, Denmark

03/08/2026

Phase III

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)

2025-523941-81-00type 2 diabetes mellitus

AstraZeneca AB

Nutritional and Metabolic Diseases

Slovakia, Poland, Czechia, Germany, Hungary, Greece, Denmark

03/08/2026

Phase III

RUBY study « Randomized controlled trial testing the efficacy of corticosteroid therapy versus placebo in fibrotic hypersensitivity pneumonitis.»

2025-521591-64-00Adult patients with a diagnosis of fibrotic Hypersensitivit…

Assistance Publique Hopitaux De Paris

Respiratory Tract Diseases

France

03/08/2026

Phase III

A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

2025-523724-47-00Acute Myeloid Leukemia

AbbVie Deutschland GmbH & Co. KG

Neoplasms

France, Austria, Spain

03/08/2026

Phase III

A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

2025-523884-39-00Systemic sclerosis

DrugNerandomilast

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Skin and Connective Tissue Diseases

Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania

03/08/2026

Phase III

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

2026-525922-39-00Moderately to Severely Active Crohn’s Disease

Janssen Cilag International

Immune System Diseases

Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece

03/08/2026

Phase III

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

2026-525923-26-00Moderately to Severely Active Ulcerative Colitis

DrugsJNJ-78934804·Guselkumab

Janssen Cilag International

Immune System Diseases

France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal

03/08/2026

Phase III

Perioperative Intravenous Metamizole in Laparoscopic Cholecystectomy: A rondomized, double blind, clinical trial.

2026-526531-18-00Post operative pain relief in Patients undergoing laparosco…

UZ Leuven

Anesthesia and Analgesia

Belgium

31/07/2026

Phase III

J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

2025-524858-34-00Lipoprotein(a), Atherosclerosis, Cardiovascular Diseases

Eli Lilly & Co.

Cardiovascular Diseases

Hungary, Czechia, Spain, Netherlands

30/07/2026

Phase III

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)

2023-510098-33-01Follicular Lymphoma

AstraZeneca AB

Neoplasms

Denmark, Czechia, France, Germany, Hungary, Italy, Spain, Poland

29/07/2026

Phase III

B-HAPPI: Bipolar disorder and high-dose adjunctive pramipexole for anhedonic depression – a phase III, double-blind, randomized controlled trial

2026-526383-20-00Bipolar disorder

Region Skane

Mental Disorders

Sweden

29/07/2026

Phase III

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

2026-526304-79-00Heart failure with preserved ejection fraction (HFpEF) and …

AstraZeneca AB

Cardiovascular Diseases

Spain, Hungary, Germany, Poland, Italy, Bulgaria, Netherlands, Austria, Romania, Sweden, France, Greece, Slovakia, Czechia

29/07/2026

Phase III

A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial

2026-526368-18-00Chronic Coronary Syndrome in patients undergoing percutaneo…

DrugClopidogrel

Azienda Ospedaliera Universitaria Gaetano Martino Messina

Cardiovascular Diseases

Italy

27/07/2026

Phase III

A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes

2025-522488-14-00Participants with obesity with or without type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium

27/07/2026

Phase III

4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome

2025-523837-25-00Barth Syndrome

DrugElamipretide

Stealth Biotherapeutics Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Ireland, Netherlands, France, Italy

27/07/2026

Phase III

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

2025-523819-11-00Small Cell Lung Cancer

DrugsABBV-706·Topotecan

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Italy, Greece, Spain, Belgium, France, Austria, Germany

27/07/2026

Phase III

Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR). The ReVeRA-301 Trial.

2024-516251-40-01Atrial Fibrillation

Milestone Pharmaceuticals Inc.

Cardiovascular Diseases

Netherlands, Spain

27/07/2026

Phase III

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)

2025-524688-19-00Participants Living with Obesity or Overweight with at leas…

AstraZeneca AB

Nutritional and Metabolic Diseases

Spain, Germany, Italy, Poland

27/07/2026

Phase III

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

2025-523960-19-00Advanced or Metastatic HR+/HER2- Breast Cancer

BeOne Medicines I GmbH

Neoplasms

Poland, Italy, Germany, France, Spain

27/07/2026

Phase III

An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam

2025-524054-34-00Spinal Muscular Atrophy

DrugSalanersen

Biogen Idec Research Limited

Nervous System Diseases

Finland, Spain, Italy, Poland, Ireland, Germany, France

24/07/2026

Phase III

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)

2025-523994-41-00Chronic kidney disease (CKD) in adults, with specified rang…

AstraZeneca AB

Cardiovascular Diseases

Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany

24/07/2026

Phase III

Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan)

2025-525097-11-00Multiple myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Polish Myeloma Consortium

Hemic and Lymphatic Diseases

Poland

23/07/2026

Phase III

A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia

2025-524282-24-00Classic Congenital Adrenal Hyperplasia (CAH)

DrugCrinecerfont

Neurocrine Biosciences Inc.

Hormonal diseases

Czechia, Germany, Sweden, Portugal, Romania, Bulgaria, Italy, Austria, Spain

23/07/2026

Phase III

Prospective, multicentre, open-label, single arm trial on contraceptive efficacy, safety and tolerability of LPRI-CF113 (Drospirenone 4 mg + 2.8 mg) during 13 cycles.

2026-525727-24-00No medical condition

Chemo Research S.L.

Not possible to specify

Sweden, Czechia, Spain, Hungary, Poland, Finland, Romania

23/07/2026

Phase III

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease

2025-522263-14-00Huntington’s Disease

DrugSKY-0515

Skyhawk Therapeutics Inc.

Nervous System Diseases

Germany, Spain

23/07/2026

Phase III

Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2)

2025-523435-18-00Major cardiovascular events (MACE), spontaneous intracerebr…

Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International

Cardiovascular Diseases

Spain, Belgium

22/07/2026

Phase III

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)

2025-523933-24-00type 2 diabetes mellitus

AstraZeneca AB

Nutritional and Metabolic Diseases

Poland, Hungary, Italy, Bulgaria, Germany

22/07/2026

Phase III

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis

2026-525242-29-00Primary Sclerosing Cholangitis

Ipsen Bioscience Inc.

Digestive System Diseases

Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway

21/07/2026

Phase III

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens

2025-524336-19-00HIV-1

DrugsCobicistat·Doravirine·Ritonavir·Tenofovir DF

Gilead Sciences Inc.

Virus Diseases

Poland, Italy, France, Spain, Germany, Netherlands

21/07/2026

Phase III

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

2025-524335-39-00HIV-1

DrugsTeropavimab·Zinlirvimab·Rilpivirine·Cabotegravir

Gilead Sciences Inc.

Virus Diseases

Netherlands, Poland, Germany, France, Spain, Italy

21/07/2026

Phase III

A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period

2025-524873-17-00Lichen Sclerosus

DrugDelgocitinib

Leo Pharma A/S

Skin and Connective Tissue Diseases

Italy, France, Spain, Poland, Germany

21/07/2026

Phase III

A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity

2025-524249-29-00Participants with overweight or obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Sweden, Greece, Hungary, Portugal

20/07/2026

Phase III

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

2025-522227-99-00Huntington’s Disease

Novartis Pharma AG

Nervous System Diseases

Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary

20/07/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

2025-524711-36-00Narcolepsy Type 1

DrugALKS 2680

Alkermes Inc.

Nervous System Diseases

Sweden, Finland, Belgium, Spain, Austria, Netherlands, France, Norway, Germany, Italy, Poland

20/07/2026

Phase III

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)

2025-523662-24-00Homozygous Familial Hypercholesterolemia (HoFH)

DrugZodasiran

Arrowhead Pharmaceuticals Inc.

Cardiovascular Diseases

Netherlands, Denmark, Norway, Sweden, Poland

20/07/2026

Phase III

Intrathecal Administration of MELPIDA For Hereditary Spastic Paraplegia Type 50 (SPG50): A multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)

2025-524576-28-00Hereditary Spastic Paraplegia Type 50 (SPG50)

DrugsMelpida·Diphenhydramine·Paracetamol·Sirolimus

Elpida Therapeutics SPC

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain

17/07/2026

Phase III

Triple oral therapy with bempedoic acid vs usual care in early lipid management of patients with acute coronary syndrome

2026-525740-15-00Acute Coronary Syndrome

Fondazione Per Il Tuo Cuore Onlus Denominabile Anche Fondazione Italiana Per La Lotta Alle Malattie Cardiovascolari Onlus Ed Anche Heart Care Foundation Hcf Onlus

Cardiovascular Diseases

Italy

17/07/2026

Phase III

Paracervical block with ropivacaine for pain relief in second trimester medical abortion - a double blind placebo controlled randomized trial

2025-524599-52-03abortion

DrugRopivacaine

Karolinska Institutet

Female Urogenital Diseases and Pregnancy Complications

Sweden

17/07/2026

Phase III

FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria

2026-525972-25-00Febrile male urinary tract infections caused by Escherichia…

DrugsFosfomycin·Ciprofloxacin·Levofloxacin

Assistance Publique Hopitaux De Paris

Male Urogenital Diseases

France

16/07/2026

Phase III

PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin

2025-525020-99-00Breast Cancer

University Hospital Of Clermont-Ferrand

Not possible to specify

France

16/07/2026

Phase III

The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.

2025-524463-20-00Asthma

DrugsDopamine·Depemokimab

Glaxosmithkline Research & Development Limited

Respiratory Tract Diseases

Ireland, Spain, Germany, Czechia, Bulgaria, France, Belgium, Romania, Italy

14/07/2026

Phase III

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

2025-524648-37-00Metastatic colorectal cancer

Merck Healthcare KGaA

Neoplasms

Belgium, Germany, France, Denmark, Poland, Spain, Netherlands, Italy, Austria

14/07/2026

Phase III

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis

2025-524448-36-00Focal segmental glomerulosclerosis (FSGS)

DrugPegcetacoplan

Apellis Pharmaceuticals Inc.

Female Urogenital Diseases and Pregnancy Complications

France, Portugal, Spain, Slovakia, Italy, Germany, Poland

14/07/2026

Phase III

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

2025-525088-34-00Metastatic Pancreatic Adenocarcinoma

Revolution Medicines Inc.

Digestive System Diseases

Poland, Belgium, Norway, Sweden, Austria, Germany, Denmark, Netherlands, France, Italy, Spain

14/07/2026

Phase III

Model-informed precision dosing for linezolid: a randomized clinical trial

2024-517888-23-00Bacterial infection (pneumonia, skin or soft tissue infecti…

DrugLinezolid

University Medical Center Hamburg-Eppendorf

Bacterial Infections and Mycoses

Germany

13/07/2026

Phase III

Effect of Vitamin D supplementation on MyocardIal Fibrosis in PaTients with Acute Myocarditis (EDIT-AM): a multicenter, open-label, randomized controlled trial

2025-523092-33-00Myocardial fibrosis, Acute myocarditis

Spanish Society Of Cardiology

Cardiovascular Diseases

Spain

10/07/2026

Phase III

Preventing urinary tract infections in infants and young children with probiotic E. coli Nissle: FinNissle randomized controlled trial

2026-526444-13-01Urinary tract infection or Pyelonephritis

Pohjois-Pohjanmaan hyvinvointialue

Bacterial Infections and Mycoses

Finland

10/07/2026

Phase III

AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

2025-522190-11-01acute lymphoblastic leukemia in children and adolescents

DrugsAsparaginase Erwinia chrysanthemi·Pegaspargase·Mercaptopurine·Blinatumomab

Universitaetsklinikum Schleswig-Holstein AöR

Neoplasms

Germany

09/07/2026

Phase III

A multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy (Beltavac®) with Polymerized Allergenic Extract of a Mixture of Dermatophagoides and Blomia tropicalis in Patients with Allergic Rhinitis/rhinoconjunctivitis.

2026-526105-15-00Allergic rhinitis/rhinoconjunctivitis due to house dust mit…

Probelte Pharma S.L.

Eye Diseases

Spain

08/07/2026

Phase III

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

2023-505575-69-01Osteosarcoma

DrugCabozantinib

Institut Gustave Roussy

Neoplasms

Sweden, Poland, Denmark, Finland, Netherlands, Italy, France, Spain

08/07/2026

Phase III

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

2025-522165-30-00Chronic inflammatory demyelinating polyradiculoneuropathy (…

Grifols Therapeutics LLC

Nervous System Diseases

Romania, Czechia, Poland

07/07/2026

Phase III

Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. (FAST 7)

2026-525594-39-00Cataract

DrugLevofloxacin

Ntc S.r.l.

Eye Diseases

Spain, Poland, Greece, Sweden, Italy

07/07/2026

Phase III

C6461016 - A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

2025-524717-86-00LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JU…

Pfizer Inc.

Neoplasms

France, Spain, Italy

07/07/2026

Phase III

A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)

2025-523369-32-00Fibrosing interstitial lung disease

DrugNerandomilast

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Respiratory Tract Diseases

Belgium, Greece, Germany, France, Finland, Spain, Czechia, Poland, Italy, Netherlands, Denmark, Portugal

07/07/2026

Phase III

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy

2025-524028-23-00Multiple Myeloma

F. Hoffmann-La Roche AG

Neoplasms

France, Germany, Italy, Greece, Denmark, Czechia, Spain, Poland

07/07/2026

Phase III

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

2025-522563-15-00Metastatic Pancreatic Ductal Adenocarcinoma; PDAC

DrugsCalcium folinate·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Portugal, Spain, France, Italy, Germany, Austria

06/07/2026

Phase III

TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer

2025-524213-84-00Patients with advanced or metastatic ER+ HER2- breast cancer

DrugsCamizestrant·Abemaciclib

Unicancer

Neoplasms

France

06/07/2026

Phase III

Macroleave: Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial

2025-521493-33-00bronchiectasis unrelated to cystic fibrosis

DrugAzithromycin

Centre Hospitalier Intercommunal Creteil

Respiratory Tract Diseases

France

06/07/2026

Phase III

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

2024-518016-39-00Respiratory tract diseases

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Denmark, Sweden, Poland, Estonia, Portugal, Latvia, Spain, Hungary, Germany, Finland, Italy, Belgium, France

06/07/2026

Phase III

2024-518213-25-00Respiratory tract diseases

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Germany, Romania, Greece, Norway, Netherlands, Poland, Lithuania, Czechia, Slovakia, Spain

06/07/2026

Phase III

The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease

2026-525442-30-00Ischemic heart disease/Chronic coronary syndrome (Myocardia…

Odense University Hospital

Cardiovascular Diseases

Denmark

06/07/2026

Phase III

Dual-agent fluorescence-guided surgery for colorectal liver metastases

2025-524755-31-00Colorectal liver metastases

Leids Universitair Medisch Centrum (LUMC)

Digestive System Diseases

Netherlands

03/07/2026

Phase III

AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)

2025-521929-32-01First Episode Psychosis (FEP)

DrugCannabidiol

University Of Oxford

Mental Disorders

Netherlands, Greece, Germany, Italy, Austria, Spain

01/07/2026

Phase III

"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"

2025-523815-12-00Relapsed or Refractory Multiple Myeloma

Janssen Cilag International

Neoplasms

Poland, Spain, Czechia, France, Italy, Germany, Greece

01/07/2026

Phase III

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

2025-522167-15-00Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)

DrugBevacizumab

Genmab A/S

Neoplasms

Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland

01/07/2026

Phase III

Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)

2023-508533-14-00Eosinophilic Disease

DrugBenralizumab

AstraZeneca AB

Immune System Diseases

Poland, Netherlands, France

30/06/2026

Phase III

A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection

2025-521971-29-00Non Small Cell Lung Cancer (NSCLC)

DrugTaletrectinib

Nuvation Bio Inc.

Respiratory Tract Diseases

Spain, Belgium, France, Italy, Germany

30/06/2026

Phase III

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

2025-521769-29-00Pulmonary Hypertension Associated with Interstitial Lung Di…

DrugTreprostinil Palmitil

Insmed Inc.

Respiratory Tract Diseases

Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania

30/06/2026

Phase III

Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci

2026-526149-91-00Infectious endocarditis caused by Gram-positive cocci (stap…

DrugsAmpicillin·Cefaclor·Cefotaxime·Dalbavancin

Friedrich-Schiller-Universitaet Jena

Bacterial Infections and Mycoses

Germany

30/06/2026

Phase III

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma

2025-524397-42-00Participants with relapsed HRNB and participants with HRNB…

DrugsTemozolomide·Irinotecan

Renaissance Pharma Limited

Nervous System Diseases

France, Spain, Denmark, Ireland, Germany

30/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

2025-524855-30-00Cutaneous Manifestations of Lupus Erythematosus With or Wit…

Merck Healthcare KGaA

Skin and Connective Tissue Diseases

Germany, Romania, France, Bulgaria, Belgium, Spain, Poland, Greece, Italy, Czechia

29/06/2026

Phase III

2025-523871-44-00Cutaneous Manifestations of Lupus Erythematosus With or Wit…

Merck Healthcare KGaA

Immune System Diseases

Spain, Belgium, France, Germany, Slovakia, Romania, Bulgaria, Italy, Poland, Greece

29/06/2026

Phase III

AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer

2025-521712-19-00Colorectal Cancer

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Greece, Portugal, Germany, Belgium, Spain

29/06/2026

Phase III

Methoxyflurane versus Standard Care for Non-Traumatic Pain in the Emergency Department (PAIN-THROX) : A Multicenter, Randomized, Controlled, Superiority Trial

2025-525001-21-00Non-traumatic pain

DrugMethoxyflurane

Centre Hospitalier Regional Universitaire De Tours

Not possible to specify

France

29/06/2026

Phase III

CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL

2025-525058-20-00Community- acquired pneumonia related sepsis with evidence …

Elliniko Institouto Meletis Tis Sipsis

Respiratory Tract Diseases

Greece

29/06/2026

Phase III

A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

2026-525531-16-00Non-Muscle Invasive Papillary Bladder Cancer

Hamlet BioPharma AB

Male Urogenital Diseases

Czechia

29/06/2026

Phase III

Self-Assessment Method for Statin side-effects Or Nocebo 2

2025-524955-30-01Cardiovascular diseases

DrugRosuvastatin

Copenhagen University Hospital, Region Hovedstaden

Musculoskeletal Diseases

Denmark

28/06/2026

Phase III

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

2025-525009-18-00Pancreatic Ductal Adenocarcinoma

Incyte Corp.

Neoplasms

Poland, Italy, Netherlands, Sweden, Denmark, Finland, Spain, France, Germany, Belgium, Norway, Austria

26/06/2026

Phase III

A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants with Solid and Hematologic Cancers (ROXI-CAT-II)

2024-519299-16-00Cancer Associated Thrombosis

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Bulgaria, Romania

26/06/2026

Phase III

Colchicine after Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial

2024-516033-12-00Atrial Fibrillation

Universitaetsspital Basel

Cardiovascular Diseases

Germany

26/06/2026

Phase III

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial

2025-524312-11-00Patients after the first year following liver transplantati…

Medizinische Hochschule Hannover

Therapeutics

Germany

26/06/2026

Phase III

Evaluating the effect of inhaled levodopa (Inbrija®) for early morning off in Parkinson’s disease

2026-526465-18-00parkinson's disease

DrugLevodopa

Region Hovedstaden

Nervous System Diseases

Denmark

25/06/2026

Phase III

A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS

2025-523726-40-00Multiple Sclerosis

F. Hoffmann-La Roche AG

Immune System Diseases

Spain, France, Poland, Italy

24/06/2026

Phase III

Women victims of violences : PTSD treatment by traumatic memory reactivation under the influence of propranolol (VIOFEM)

2025-523107-30-01Post-traumatic stress disorder (PTSD)

DrugPropranolol

Centre Hospitalier Universitaire De Toulouse

Mental Disorders

France

24/06/2026

Phase III

ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis

2026-526167-38-00liver cirrhosis

Amsterdam UMC Stichting

Digestive System Diseases

Netherlands

23/06/2026

Phase III

Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone

2025-523832-38-00Small for gestational age (SGA) and idiopathic short statur…

DrugsSomatrogon·Somatropin

Schneider Children's Medical Center Of Israel

Musculoskeletal Diseases

Greece, Poland, France, Czechia

23/06/2026

Phase III

ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial

2025-524976-40-00patients with influenza-induced acute hypoxemic respiratory…

DrugDexamethasone

Centre Hospital Region Metz Thionville

Respiratory Tract Diseases

France

23/06/2026

Phase III

SERENDIPITY: phase III multicentric randomized study assessing the reduction of chronic prostate inflammation with Permixon®

2025-525123-27-00Benign prostatic hypertrophy

Azienda Ospedaliero Universitaria Careggi, University Of Florence

Male Urogenital Diseases

Italy

23/06/2026

Phase III

A Prospective, Randomized, Controlled, Multinational, Phase 2/3, Open-Label Trial to Evaluate the Efficacy and Safety of SIL204-SL Administered as an Integrated Therapeutic Regimen in Combination with Chemotherapy vs. Chemotherapy Treatment Alone in Participants with Locally Advanced Pancreatic Cancer

2025-525157-39-00Non-Resectable Locally Advanced Pancreatic Cancer (LAPC)

Silexion Therapeutics Ltd.

Neoplasms

Germany

23/06/2026

Phase III

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

2025-521353-16-00Hereditary Angioedema

DrugDopamine

Adarx Pharmaceuticals Inc.

Immune System Diseases

Poland, Italy, Hungary, France, Austria, Czechia, Belgium, Spain, Bulgaria, Germany, Croatia

22/06/2026

Phase III

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

2025-524322-18-00Non-active Secondary Progressive Multiple Sclerosis (SPMS)

DrugOrelabrutinib

Zenas Biopharma (USA) LLC

Nervous System Diseases

Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia

22/06/2026

Phase III

Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events

2025-524625-41-00Coronary atherosclerosis

Daiichi Sankyo Europe GmbH

Cardiovascular Diseases

Italy, Spain, Germany

22/06/2026

Phase III

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)

2025-524337-11-00Systemic Sclerosis

DrugsNintedanib·Tocilizumab·Fludarabine·Rituximab

Celgene Corp.

Immune System Diseases

Spain, Germany, France, Italy, Belgium

19/06/2026

Phase III

Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO

2025-524048-36-00Advanced HER2-negative and PD-L1 positive gastroesophageal …

Fondazione GONO G.I.

Neoplasms

Spain, Germany, Italy

18/06/2026

Phase III

A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system

2025-523654-13-00Demyelinating diseases

Medizinische Hochschule Hannover

Nervous System Diseases

Germany, Austria

17/06/2026

Phase III

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

2025-522373-10-00Progressive pulmonary fibrosis and Idiopathic pulmonary fib…

DrugAdmilparant

Bristol-Myers Squibb Services Unlimited Company

Respiratory Tract Diseases

Finland, Portugal, Hungary, Ireland, Poland, Greece, France, Belgium, Denmark, Italy, Spain, Netherlands, Austria, Germany

17/06/2026

Phase III

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

2024-519787-40-00Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, E…

AstraZeneca AB

Neoplasms

France, Italy, Spain, Hungary, Poland, Belgium, Germany, Netherlands

16/06/2026

Phase III

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

2025-522643-18-00Stage I NSCLC

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Neoplasms

Greece, Poland, Italy, Hungary, Germany, Netherlands, France, Spain

16/06/2026

Phase III

Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms

2025-524344-35-00Heart failure

DrugAcetazolamide

Centre Hospitalier Universitaire De Montpellier

Cardiovascular Diseases

France

15/06/2026

Phase III

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

2024-511296-15-00Musculoskeletal diseases

Sanofi-Aventis Recherche & Developpement

Musculoskeletal Diseases

France, Netherlands, Germany, Czechia, Belgium, Austria, Hungary, Greece, Spain

15/06/2026

Phase III

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

2025-524371-23-00Limb Girdle Muscular Dystrophy (LGMD) Type 2I

DrugRibitol

ML Bio Solutions Inc.

Musculoskeletal Diseases

Germany, Denmark, Netherlands, Italy, Norway

15/06/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

2025-522038-29-00Locally advanced, unresected (unresectable or medically ino…

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Neoplasms

Italy, Netherlands, France, Germany, Spain, Poland, Greece

12/06/2026

Phase III

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

2025-522267-15-00Relapsed/refractory B-cell Acute Lymphoblastic Leukemia

Merck Sharp & Dohme LLC

Neoplasms

Greece, Netherlands, Sweden, France, Italy, Spain, Denmark

12/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

2025-523674-16-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Greece, Germany, Belgium, Netherlands, Poland, Italy, France, Spain, Bulgaria, Austria

12/06/2026

Phase III

Evaluation of the Non-Inferiority of Topical Chloramphenicol Versus Topical Ciprofloxacin in the Resolution of Otorrhea in Adults With Chronic Suppurative Otitis Media (CSOM) – Protocol OMCOS

2026-525540-15-00chronic suppurative otitis media (CSOM)

Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

Otorhinolaryngologic Diseases

Spain

11/06/2026

Phase III

First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)

2025-523593-16-00Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stag…

DrugsTemozolomide·Capecitabine

Institut Gustave Roussy

Neoplasms

France

10/06/2026

Phase III

A Phase 3 prospective, randomized, multicenter, active-controlled study to evaluate the efficacy and safety of BV100 plus low-dose polymyxin B compared with colistin plus high-dose ampicillin/sulbactam in the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex

2025-524092-23-00Hospital-acquired bacterial pneumonia including ventilator-…

Bioversys S.A.S.

Bacterial Infections and Mycoses

Greece, Croatia

10/06/2026

Phase III

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination with mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants with KRAS G12D-mutated Metastatic Pancreatic Adenocarcinoma

2025-523684-38-00Adult participants with metastatic PDAC with KRAS G12D muta…

Astellas Pharma Global Development Inc.

Neoplasms

Germany, Italy, Spain, Poland, France

10/06/2026

Phase III

Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)

2026-526212-37-00Advanced lymphoid leukemia

Institut De Recherches Internationales Servier IRIS

Neoplasms

France

09/06/2026

Phase III

A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.

2025-522777-10-00Follicular Lymphoma

Merck Sharp & Dohme LLC

Neoplasms

France, Spain, Germany, Greece, Italy, Poland

09/06/2026

Phase III

Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent)

2025-523990-40-00Newly diagnosed Multiple Myeloma in patients eligible for s…

Universitaetsklinikum Heidelberg AöR

Hemic and Lymphatic Diseases

Germany

09/06/2026

Phase III

Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis

2025-524454-34-00Bronchiectasis

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Respiratory Tract Diseases

Spain

09/06/2026

Phase III

Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial

2025-523896-44-00Congenital hemophilia A (HA), Synovitis

DrugEfanesoctocog alfa

GWT-Tud GmbH

Hemic and Lymphatic Diseases

Austria, Germany

08/06/2026

Phase III

A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)

2025-522176-86-01Moderate Calcific Aortic Valve Stenosis (CAVS)

Kardigan Inc.

Cardiovascular Diseases

Norway, Czechia, Portugal, Austria, Poland, France, Spain

08/06/2026

Phase III

HOVON 182 CLL: Prospective randomized phase 3 study of treatment with rituximab (6 cycles) in combination with 6 or 26 cycles of venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia RED RIVER CLL study: Reduced Duration Rituximab VEnetoclax in Relapsed/refractory CLL

2025-524283-38-00Relapsed or refractory small lymphocytic lymphoma, Relapsed…

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hemic and Lymphatic Diseases

Netherlands

08/06/2026

Phase III

PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, NON-INFERIORITY CLINICAL-TRIAL TO ASSESS THE EFFICACY AND SAFETY OF SHORT OUTPATIENT AMOXICILLIN REGIMENS IN CHILDREN WITH ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS (STOP – TRIAL)

2026-525355-93-00ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS

DrugAmoxicillin

Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus

Bacterial Infections and Mycoses

Spain

08/06/2026

Phase III

Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?

2026-525783-18-00Laparoscopic cholecystectomy

DrugsSufentanil·Fentanyl

Fundacion Biomedica Galicia Sur

Digestive System Diseases

Spain

08/06/2026

Phase III

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer

2025-522818-23-00Small Cell Lung Cancer (SCLC)

DrugsZL-1310·Topotecan

Zai Lab (US) LLC

Neoplasms

Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France, Croatia, Romania, Norway

08/06/2026

Phase III

A prospective, open-label, non-randomized, multicentre trial to assess the safety and PD of Cangrelor as procedural platelet inhibitor in paediatric subjects from birth to <18 years of age undergoing diagnostic and/or therapeutic percutaneous vascular procedures for management of congenital heart disease

2025-523109-14-00Congenital Heart Disease

Chiesi Farmaceutici S.p.A.

Cardiovascular Diseases

Netherlands, Germany, Portugal, Austria, Italy

08/06/2026

Phase III

OFA-VATS : Impact of opioid free anesthesia on postoperative quality of recovery and analgesia after video or robot assisted thoracic surgery

2025-524240-35-00indication for pulmonary resection surgery (segmentectomy o…

DrugsRemifentanil·Sufentanil·Dexmedetomidine

Centre Hospitalier Universitaire De Rennes

Anesthesia and Analgesia

France

05/06/2026

Phase III

ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms

2025-525069-65-00depressive symptoms, Alcohol use disorder

Centre Hospitalier Universitaire De Nimes

Mental Disorders

France

05/06/2026

Phase III

PACHA-02_Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of recurrence

2025-523913-27-00Participants with R0/R1 resected liver metastases from colo…

DrugsCalcium levofolinate·Folinic acid·Fluorouracil·Irinotecan

Unicancer

Neoplasms

France

05/06/2026

Phase III

A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)

2025-524894-17-00Neovascular age-related macular degeneration (NVAMD)

Eyebiotech Limited

Eye Diseases

Austria, Slovakia, Portugal, Czechia, Hungary, Spain, France, Denmark, Italy, Croatia

05/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

2025-523912-35-00Narcolepsy Type 2

Alkermes Inc.

Nervous System Diseases

Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland

04/06/2026

Phase III

TicAgreLor versus placebo to prevent cerebral ISCHemia in anEuRysmal low grade SAH A double blinded randomised controlled study TALISCHER - SAH

2023-509795-42-00Aneurysmal subarachnoid hemorrhage

DrugTicagrelor

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

04/06/2026

Phase III

Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR trial

2024-518706-41-01Cardiovascular disease

Vaestra Goetalandsregionen

Diagnosis

Sweden

03/06/2026

Phase III

Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease, an open-label, phase II extension trial (MONTPARK_OLE)

2026-525906-37-00Parkinson's Disease

DrugMontelukast

Karolinska University Hospital

Nervous System Diseases

Sweden

03/06/2026

Phase III

2025-524575-22-00Neovascular age-related macular degeneration (NVAMD)

Eyebiotech Limited

Eye Diseases

Spain, Poland, Estonia, Latvia, Germany

03/06/2026

Phase III

A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment in Patients with Multiple Sclerosis (MS)

2025-523892-50-00Multiple Sclerosis

DrugRituximab

Region Stockholm – SLSO

Nervous System Diseases

Sweden

02/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

2025-523911-13-00Narcolepsy Type 1

Alkermes Inc.

Nervous System Diseases

Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland

02/06/2026

Phase III

Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

2025-523670-17-00Systemic lupus erythematosus

AstraZeneca AB

Immune System Diseases

Poland, Germany, Italy, France, Spain

02/06/2026

Phase III

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS

2025-522434-32-00Hemophilia A Without Inhibitors

F. Hoffmann-La Roche AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

France, Austria, Poland, Netherlands, Spain, Denmark, Italy, Germany, Hungary

01/06/2026

Phase III

Post-INFECT: Investigating Neuroinflammation and its eFEcts in post-COVID syndrome: an imaging sTudy

2025-522349-23-00post-COVID syndrome

Amsterdam UMC Stichting

Virus Diseases

Netherlands

01/06/2026

Phase III

Allergen extract of Lepidoglyphus destructor. Study of the sensitivity and specificity of the diagnostic preparation in prick tests

2025-523426-40-00Allergy to Lepidoglyphus destructor

Inmunotek S.L.

Immune System Diseases

Spain

01/06/2026

Phase III

A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.

2022-502365-26-00Asthma

DrugSalbutamol

Novartis Pharma AG

Respiratory Tract Diseases

Poland, France, Slovakia, Spain, Hungary, Germany, Romania

01/06/2026

Phase III

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A

2025-522435-33-00Hemophilia A

F. Hoffmann-La Roche AG

Hemic and Lymphatic Diseases

Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France

01/06/2026

Phase III

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma

2025-524241-27-00Treatment-naїve mantle cell lymphoma (MCL)

DrugsOrelabrutinib·Bendamustine·Rituximab

Innocare Pharma Inc.

Neoplasms

Poland, France, Czechia, Spain, Romania

01/06/2026

Phase III

A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder

2025-524062-16-00Schizophrenia and Autism Spectrum Disorder (ASD)

Bristol-Myers Squibb Services Unlimited Company

Nervous System Diseases

Romania

29/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive

2025-523555-66-00Myelofibrosis

DrugsPelabresib·Ruxolitinib

Novartis Pharma AG

Neoplasms

Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France

29/05/2026

Phase III

Tranexamic Acid in Hind and Midfoot Arthrodesis Surgery: A Multicentre, Randomized, Placebo-Controlled Trial (TRASH Trial)

2026-526142-27-01Deformity, Osteoarthritis

HUS-yhtymae

Therapeutics

Finland

29/05/2026

Phase III

A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated allergoid Dactylis glomerata/Phleum pratense administered subcutaneously to patients with grass pollen-induced allergic rhinitis or rhinoconjunctivitis.

2025-524580-21-00Grass pollen induced allergic rhinitis or rhinoconjunctivit…

Inmunotek S.L.

Immune System Diseases

Germany

29/05/2026

Phase III

COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis: a multicenter randomized placebo-controlled, double-blinded clinical trial

2025-522956-25-00Chronic pancreatitis

DrugCelecoxib

Odense University Hospital

Digestive System Diseases

Denmark

29/05/2026

Phase III

Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)

2026-525263-41-00Hodgkin lymphoma

Polska Grupa Badawcza Chloniakow

Neoplasms

Poland

29/05/2026

Phase III

A Randomized, Multicenter, Single-Blind, Parallel-Group Phase III Non-Inferiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Metronidazole, Bismuth Oxide and Tetracycline HCl to Standard Concomitant Non-Bismuth Quadruple Therapy for First-Line Eradication of Helicobacter pylori in Adults.

2026-525291-26-00Helicobacter Pylori Infection

DrugMetronidazole

Verisfield Single Member S.A.

Bacterial Infections and Mycoses

Greece

28/05/2026

Phase III

A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease

2025-521590-13-00Moderately to Severely Active Crohn’s Disease

Janssen Cilag International

Immune System Diseases

Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary

27/05/2026

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy

2025-522949-22-00Duchenne muscular dystrophy

Solid Biosciences Inc.

Musculoskeletal Diseases

Spain, Netherlands, France, Italy, Belgium, Germany

26/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

2025-524040-35-00Severe uncontrolled asthma

Generate Biomedicines Inc.

Respiratory Tract Diseases

Italy, Slovakia, Spain, Ireland, Belgium, France, Estonia

26/05/2026

Phase III

D. pteronyssinus and D. farinae allergen extracts. Study of the sensitivity and specificity of the prick test diagnostic preparation

2025-522469-31-00Allergy to Dermatophagoides pteronyssinus, Allergy to Derma…

Inmunotek S.L.

Immune System Diseases

Spain

25/05/2026

Phase III

Comparison of iodinated contrast media injection protocols with reduced flow rates and volumes on image quality in diagnostic cerebral angiography for the evaluation of unruptured intracranial aneurysms: towards a standardization of practices (OPIAC)

2025-524884-18-01Intracranial aneurysms

Les Hopitaux Universitaires De Strasbourg

Nervous System Diseases

France

22/05/2026

Phase III

ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy

2025-523576-23-00Unresectable Stage III non-small cell lung cancer without p…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

France, Ireland, Germany, Greece, Bulgaria, Spain, Netherlands, Italy, Sweden, Romania, Hungary, Belgium, Austria, Poland

22/05/2026

Phase III

An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib

2025-524078-40-00Chronic Spontaneous Urticaria

Novartis Pharma AG

Skin and Connective Tissue Diseases

Germany, Spain, France, Poland, Bulgaria, Czechia

20/05/2026

Phase III

A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa

2025-523259-72-00Hidradenitis Suppurativa (HS)

Novartis Pharma AG

Immune System Diseases

Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy, Denmark

20/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping

2025-523087-20-00Duchenne muscular dystrophy

DrugAOC 1044

Avidity Biosciences Inc.

Musculoskeletal Diseases

Italy, Germany, France, Spain, Belgium, Poland, Netherlands

20/05/2026

Phase III

Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial

2025-524408-30-01Metastatic hormone-sensitive prostate cancer

DrugApalutamide

Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Neoplasms

Spain, Germany, France, Portugal, Italy

19/05/2026

Phase III

A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)

2025-521632-12-00Patients on Factor Xa inhibitor treatment needing an urgent…

VarmX B.V.

Hemic and Lymphatic Diseases

Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania

19/05/2026

Phase III

A multicentre, open-label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens when administering a single-dose, intramuscular vaccination as simulated post-exposure prophylaxis at least five years following priming. "BAZOOKA_221"

2025-524765-24-00Rabies infection/prophylaxis

Institute Of Tropical Medicine

Virus Diseases

Belgium

19/05/2026

Phase III

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

2025-523735-19-00Metastatic Microsatellite Stable Colorectal Cancer

DrugsINCA33890·Calcium folinate·Fluorouracil·Oxaliplatin

Incyte Corp.

Neoplasms

Poland, France, Denmark, Norway, Spain, Germany, Belgium, Netherlands, Austria, Italy

19/05/2026

Phase III

Multicentre, randomised, double-blind, placebo-controlled clinical trial to confirm the efficacy, safety, and clinical impact of the mucosal bacterial therapeutic vaccine MV140 in women with non-complicated recurrent urinary tract infections (rUTIs).

2025-524377-16-00Recurrent Non-Complicated Urinary Tract Infections (rUTIs).

DrugsFosfomycin·Pivmecillinam·Nitrofurantoin

Inmunotek S.L.

Bacterial Infections and Mycoses

Portugal

19/05/2026

Phase III

Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlled Non-Inferiority Trial (TEMtoGo).

2025-524475-23-00Neisseria gonorrhoeae Infections

DrugCeftriaxone

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

18/05/2026

Phase III

EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management of complicated pleural infections

2025-524697-42-00Pleural infections

DrugsCefotaxime·Dornase Alfa·Clindamycin·Alteplase

Centre Hospitalier Universitaire Amiens Picardie

Respiratory Tract Diseases

France

18/05/2026

Phase III

Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Blomia tropicalis

2025-522773-12-00Aetiological treatment of moderate-to-severe allergic rhini…

Inmunotek S.L.

Immune System Diseases

Spain

18/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis

2025-524316-11-00Primary Progressive Multiple Sclerosis (PPMS)

DrugOrelabrutinib

Zenas Biopharma (USA) LLC

Nervous System Diseases

Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary

18/05/2026

Phase III

ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%

2025-523586-18-00Non-Small Cell Lung Cancer

DrugPembrolizumab

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Portugal, Norway, Sweden, Bulgaria, France, Belgium, Austria, Germany, Finland, Poland, Romania, Netherlands, Spain, Italy, Hungary, Czechia

15/05/2026

Phase III

NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)

2024-516734-35-00triple-negative early breast cancer

DrugsSacituzumab Govitecan·Pembrolizumab

WSG Women's Cancer Study Group GmbH

Neoplasms

Germany, Poland

15/05/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)

2024-520446-31-00Participants with overweight or obesity, and type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Germany, Croatia, Portugal, Hungary, Bulgaria, Romania, Poland

15/05/2026

Phase III

2025-522771-28-00Aetiological treatment of moderate-to-severe allergic rhini…

Inmunotek S.L.

Immune System Diseases

Spain

14/05/2026

Phase III

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

2025-523389-26-00Relapsed/refractory primary central nervous system lymphoma

Deciphera Pharmaceuticals Inc.

Nervous System Diseases

Czechia, Germany, Italy, Belgium, Spain, Poland, Austria, France, Hungary

14/05/2026

Phase III

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

2025-524810-28-00Acute Promyelocytic Leukemia

DrugArsenic Trioxide

Quetzal Therapeutics LLC

Neoplasms

Germany, Poland, Spain, Romania, Italy, France

13/05/2026

Phase III

A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.

2025-523869-22-00advanced or metastatic extrapulmonary neuroendocrine carcin…

DrugsObrixtamig·Tocilizumab·Carboplatin

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway

13/05/2026

Phase III

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, with Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)

2025-524214-28-00Heterozygous Familial Hypercholesterolemia

DrugLerodalcibep

LIB Therapeutics Inc.

Nutritional and Metabolic Diseases

Norway

13/05/2026

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes

2025-523106-32-00Obesity or Overweight and Type 2 Diabetes

F. Hoffmann-La Roche AG

Nutritional and Metabolic Diseases

Germany, Romania, Czechia, Poland, Hungary, France, Spain, Italy

13/05/2026

Phase III

IMMUNOTIME « EVALUATION OF THE EFFECT OF TIME OF ADMINISTRATION ON THE ACTIVITY ON FIRST LINE OF PEMBROLIZUMAB IN ASSOCIATION WITH CARBOPLATIN PEMETREXED IN METASTATIC NON-SQUAMOUS LUNG CANCER. A RANDOMISED MULTICENTER PHASE III TRIAL»

2025-521891-78-00Adult patients with stage IV non squamous non-small cell lu…

DrugsPemetrexed·Carboplatin·Pembrolizumab

Assistance Publique Hopitaux De Paris

Neoplasms

France

12/05/2026

Phase III

Effect of vasopressin versus norepinephrine on post-operative mean pulmonary arterial pressure following pulmonary endarterectomy surgery, a randomized open label trial

2025-525153-39-00Chronic thromboembolic pulmonary hypertension

Fondation Hopital Saint Joseph

Respiratory Tract Diseases

France

12/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

2025-521950-41-00severe uncontrolled asthma

DrugGB-0895

Generate Biomedicines Inc.

Respiratory Tract Diseases

Latvia, Hungary, Bulgaria, Romania, Portugal, Netherlands, Croatia, Germany, Greece, Czechia

12/05/2026

Phase III

DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.

2025-520565-51-00small cell lung cancer

DrugsObrixtamig·Tocilizumab·Atezolizumab·Carboplatin

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Czechia, Sweden, Poland, Netherlands, Greece, Latvia, Finland, Norway, Belgium, Austria, Portugal, Romania, Italy, Estonia, France, Ireland, Germany, Spain, Bulgaria, Hungary

12/05/2026

Phase III

A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

2025-522586-30-00Psoriatic Arthritis

DrugZasocitinib

Takeda Development Center Americas Inc.

Musculoskeletal Diseases

Germany, Belgium, Spain, Czechia, Croatia, Portugal, Poland, Latvia, Bulgaria, France, Estonia, Hungary, Italy

12/05/2026

Phase III

MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease

2025-521331-36-00Patient with stabilized SSc-ILD (as defined by a decline of…

DrugRituximab

Assistance Publique Hopitaux De Paris

Skin and Connective Tissue Diseases

France

11/05/2026

Phase III

A randomized controlled non-inferiority trial comparing 7 versus 14 days of ciprofloxacin for male urinary tract infections with systemic involvement.

2025-524703-76-00Urinary tract infection with systemic involvement (UTI: def…

UZ Brussel

Bacterial Infections and Mycoses

Belgium

11/05/2026

Phase III

The GranStone Trial - Prevention of Kidney Stones due to Paraffin Oil Induced Granuloma

2026-525608-85-00Paraffin Oil Induced Granulomatous Disease

DrugsLosartan·Dapagliflozin

Region Hovedstaden

Musculoskeletal Diseases

Denmark

11/05/2026

Phase III

A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk (MEDICI Study)

2025-524265-24-00Dyslipidemia at High to Very High Cardiovascular Risk

A. Menarini International Licensing S.A.

Hemic and Lymphatic Diseases

Spain, Poland, Netherlands, Italy, Slovakia, Czechia, Germany

11/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")

2025-522854-37-00Prevention of a Major infection in patients with Hypogammag…

Octapharma Pharmazeutika Produktionsgesellschaft mbH

Immune System Diseases

Czechia, Lithuania, Greece, Poland, Germany, Latvia, Bulgaria, Italy

11/05/2026

Phase III

J5E-MC-JZXB - FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

2025-522255-25-00Neoplasm Metastasis, Fallopian Tube Neoplasms, Ovarian Neop…

Eli Lilly & Co.

Neoplasms

Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany

11/05/2026

Phase III

A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies

2025-522983-33-00Chronic rhinosinusitis with nasal polyps

DrugItepekimab

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland

11/05/2026

Phase III

A national randomised multi-centre phase II/III trial using MesoPher in ABC borderline resectable pancreatic cancer (PREOPANC-6 trial)

2025-523134-28-00ABC borderline resectable pancreatic cancer

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

11/05/2026

Phase III

A phase III, multicentre, double-blind, randomised, placebo-controlled and open-label study to evaluate the efficacy and safety of a single dose of IPN10200 in the improvement of moderate to severe glabellar lines in adult participants, and to evaluate the long-term efficacy and safety of repeat doses of IPN10200 in the same indication.

2025-522618-22-00Treatment of moderate to severe glabellar lines

Ipsen Innovation

Physical Phenomena

France, Germany

07/05/2026

Phase III

2025-523104-71-00Obesity or Overweight Without Type 2 Diabetes

F. Hoffmann-La Roche AG

Nutritional and Metabolic Diseases

Poland, Hungary, France, Belgium, Italy, Netherlands, Czechia, Germany, Spain

07/05/2026

Phase III

Optimizing Aspirin Use for Preeclampsia Prevention

2025-524646-94-00Obstetrics – Preeclampsia

DrugAcetylsalicylic acid

Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Not possible to specify

Spain

07/05/2026

Phase III

Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)

2025-523443-35-00Persistent Corneal Epithelial Defect (PCED)

Dompe' Farmaceutici S.p.A.

Eye Diseases

Czechia, Italy, Netherlands, Poland, Germany, Spain, Hungary, France

05/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes

2025-523486-17-00Obesity

DrugRibupatide

Kailera Therapeutics Inc.

Nutritional and Metabolic Diseases

Bulgaria, Hungary, Spain, Germany, Czechia, Poland

05/05/2026

Phase III

A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with Achondroplasia

2025-523811-12-00Achondroplasia

DrugVosoritide

Biomarin Pharmaceutical Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Poland, Italy, Romania, France, Norway, Netherlands, Sweden

05/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

2025-523552-31-00Systemic Lupus Erythematosus

Janssen Cilag International

Immune System Diseases

Denmark, Hungary, Portugal, Italy, Norway, Greece, Slovakia, Czechia, France, Poland, Bulgaria, Germany, Spain, Romania, Finland

05/05/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)

2024-520440-42-00Obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Denmark, France, Germany, Belgium

04/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes

2025-523510-87-00Obesity

DrugRibupatide

Kailera Therapeutics Inc.

Nutritional and Metabolic Diseases

Hungary, Poland, Bulgaria, Germany, Czechia, Spain

04/05/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)

2024-520441-23-00Overweight or obesity, and type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Italy, Croatia, Hungary, Slovakia, Romania

04/05/2026

Phase III

Modafinil for debilitating fatigue in quiescent inflammatory bowel disease: a multicentre, randomised, double-blind, placebo-controlled, clinical trial (MODIFI-IBD trial)

2026-525163-41-00Inflammatory bowel disease, Fatigue

Radboud universitair medisch centrum Stichting

Digestive System Diseases

Netherlands

04/05/2026

Phase III

A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy

2024-519638-22-00IgA nephropathy

Novartis Pharma AG

Immune System Diseases

Belgium, France, Czechia, Croatia, Greece, Germany, Italy, Spain

04/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)

2024-516993-31-00Renal Cell Carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece

04/05/2026

Phase III

A phase III randomised, double-blind, placebo-controlled, multicentre efficacy and safety clinical trial of angiotensin II in paediatric patients of 0 to 17 years of age with refractory hypotension in distributive shock receiving fluid resuscitation and standard-of-care vasopressors

2025-523750-14-00refractory hypotension in distributive shock

Paion Pharma GmbH

Cardiovascular Diseases

Italy, Germany, France, Spain

30/04/2026

Phase III

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)

2025-523285-25-00Relapsed or Refractory Multiple Myeloma

DrugsAZD0120·Carfilzomib·Pomalidomide·Bortezomib

AstraZeneca AB

Neoplasms

Norway, Poland, Spain, Germany, France, Italy

30/04/2026

Phase III

An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospital Stay Following On-Pump Coronary Artery Bypass Grafting Surgery

2025-525053-39-00Coronary artery disease

EBI Anti Sepsis B.V.

Cardiovascular Diseases

Belgium, Netherlands

29/04/2026

Phase III

A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living with Obesity Who Do Not Have Diabetes

2025-523511-11-00Obesity

Kailera Therapeutics Inc.

Nutritional and Metabolic Diseases

Poland, Bulgaria

29/04/2026

Phase III

THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL

2025-525006-37-00Infection and sepsis

DrugMeropenem

Elliniko Institouto Meletis Tis Sipsis

Pathological Conditions, Signs and Symptoms

Greece

29/04/2026

Phase III

HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma

2025-524876-43-00relapsed/refractory multiple myeloma

DrugsElotuzumab·Carfilzomib·Pomalidomide·Bortezomib

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

29/04/2026

Phase III

A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression

2025-522872-10-00Depressive episodes associated with Bipolar disorder I or I…

Xenon Pharmaceuticals Inc.

Mental Disorders

Bulgaria, Germany, France, Spain

28/04/2026

Phase III

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.

2024-520218-23-00Pulmonary Arterial Hypertension

Inhibikase Therapeutics Inc.

Cardiovascular Diseases

Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania

28/04/2026

Phase III

CIRCULATE III - Tailoring the decision for adjuvant chemotherapy using circulating tumour DNA, in patients with stage III colorectal cancer

2025-521045-24-00Stage III colorectal cancer

Unicancer

Neoplasms

France, Sweden

28/04/2026

Phase III

A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

2025-524160-38-00Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dM…

Merck Sharp & Dohme LLC

Neoplasms

Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark

28/04/2026

Phase III

ANTIPROM - Comparison of two prophylactic antibiotic regimens in case of preterm prelabor rupture of membranes before 34 weeks of gestation: a randomized controlled trial

2025-520842-31-00Population of study participants Pregnant women with PPROM …

DrugsCeftriaxone·Azithromycin·Amoxicillin

Assistance Publique Hopitaux De Paris

Female Urogenital Diseases and Pregnancy Complications

France

28/04/2026

Phase III

A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D

2025-522750-39-00Erosive esophagitis (EE) due to gastroesophageal reflux dis…

Cinclus Pharma Holding AB (publ)

Digestive System Diseases

Hungary, Germany, Romania, Bulgaria, Czechia, Poland

28/04/2026

Phase III

A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1

2025-522957-20-00Myotonic Dystrophy Type 1

Dyne Therapeutics Inc.

Nervous System Diseases

Netherlands, Spain, Italy, Denmark, Germany, Belgium, France

28/04/2026

Phase III

Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity

2023-509176-42-00Obesity and T2D

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Slovakia, Austria, Spain, Romania, Portugal, Italy, Denmark, Belgium, Sweden, Poland, Netherlands, Croatia, Hungary, Bulgaria

28/04/2026

Phase III

A randomized, open-label, Phase III trial to assess the efficacy and safety of BupiZenge compared to lidocaine for pain associated with oral mucositis in head and neck cancer

2025-524386-24-00Head and neck cancer, Oral mucositis

OncoZenge AB

Anesthesia and Analgesia

Germany, Denmark, Norway, Sweden

28/04/2026

Phase III

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)

2023-508047-40-00Ovarian cancer

Merck Sharp & Dohme LLC

Neoplasms

Norway, Ireland, Spain, Greece, France, Poland, Denmark, Austria, Hungary, Belgium, Czechia, Finland, Germany, Italy, Sweden

28/04/2026

Phase III

Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome

2025-522552-20-00Lennox-Gastaut Syndrome

Epygenix Therapeutics Inc.

Nervous System Diseases

Italy, Spain, Hungary, Romania, Czechia, Poland

28/04/2026

Phase III

Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer’s Disease Dementia

2024-517388-22-00Agitation in Alzheimer's Disease Dementia

Exciva GmbH

Nervous System Diseases

Italy, Slovakia, Spain, Poland, Czechia, Germany

28/04/2026

Phase III

A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)

2023-504135-40-00Classical Homocystinuria

Travere Therapeutics Inc.

Nutritional and Metabolic Diseases

Belgium, Ireland, Spain, Italy, Germany, France, Portugal, Poland

27/04/2026

Phase III

Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).

2025-523804-62-00Obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Belgium, Germany, Bulgaria, France, Spain, Denmark, Italy, Netherlands

27/04/2026

Phase III

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2‑Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)

2025-523495-23-00Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Revolution Medicines Inc.

Digestive System Diseases

France, Spain, Italy, Germany

27/04/2026

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)

2024-519298-21-00Cancer-Associated Thrombosis (CAT).

DrugCenvacibart

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Belgium, Czechia, France, Romania, Germany, Poland, Bulgaria, Spain

27/04/2026

Phase III

SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17 years

2024-511114-20-00Craniopharyngioma

DrugSemaglutide

Centre Hospitalier Universitaire D'Angers

Nervous System Diseases

France

27/04/2026

Phase III

Phase II/III randomized controlled open-label trial to evaluate the efficacy and safety of personalized tissue engineered veins in patients with chronic venous insufficiency

2025-524103-69-00Chronic Venous Insufficiency

VeriGraft AB

Cardiovascular Diseases

Spain

27/04/2026

Phase III

A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, 12-Week Trial to Evaluate the Efficacy and Safety of Treatment with K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg

2025-523739-20-00Hypercholesterolemia

Kowa Co. Ltd.

Cardiovascular Diseases

Spain

24/04/2026

Phase III

ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled trial

2025-524122-18-00Septic shock

DrugsNorepinephrine·Hydrocortisone·Midazolam·Propofol

Hospices Civils De Lyon

Not possible to specify

France

24/04/2026

Phase III

Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study

2025-522486-29-01Diabetes Mellitus, Cardiovascular disease, Overweight (BMI …

DrugSemaglutide

Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali

Cardiovascular Diseases

Italy

23/04/2026

Phase III

A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia

2025-524209-34-00Chemotherapy induced thrombocytopenia

Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Not possible to specify

France, Romania, Poland, Spain, Bulgaria

21/04/2026

Phase III

A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension

2025-523481-24-00Participants with Progressive Supranuclear Palsy Richardson…

Novartis Pharma AG

Nervous System Diseases

Netherlands, Germany, Spain, Italy, France, Belgium

21/04/2026

Phase III

J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

2025-523659-73-00Overweight, Obesity

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Spain, Romania, Belgium, Czechia

21/04/2026

Phase III

KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized controlled trial

2025-523149-80-00Adult patients admitted to the ICU and receiving unplanned …

Assistance Publique Hopitaux De Paris

Respiratory Tract Diseases

France

20/04/2026

Phase III

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia

2025-524366-21-00treatment-naive Chronic Lymphocytic Leukemia

BeOne Medicines I GmbH

Neoplasms

Netherlands, Poland, Italy, Germany, Spain, Romania, Czechia, France, Sweden

20/04/2026

Phase III

A Multicenter, Open-Label, Dose Escalation Study of the Safety, Tolerability, and Efficacy of Budiodarone for the Treatment of Subjects with Non-permanent Atrial Fibrillation

2025-523860-19-00Non-permanent Atrial Fibrillation

Xyra LLC

Cardiovascular Diseases

Poland

20/04/2026

Phase III

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age)

2025-523711-11-00Schizophrenia

Bristol-Myers Squibb Services Unlimited Company

Mental Disorders

Romania

20/04/2026

Phase III

A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Adjuvant Placebo Plus MK-3475A in Participants with Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)

2024-517337-41-00Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated N…

Merck Sharp & Dohme LLC

Neoplasms

Italy, Spain, Germany, Poland, Greece, France

20/04/2026

Phase III

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

2024-520014-22-00Locally advanced/metastatic urothelial carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Netherlands, Greece, Italy, Germany, Spain, Belgium, Sweden, France

20/04/2026

Phase III

C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY

2025-523660-21-00severe to moderately severe hemophilia B (FIX:C ≤ 2%), hemo…

Pfizer Inc.

Hemic and Lymphatic Diseases

Italy, Germany, France, Spain, Sweden, Greece

20/04/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis

2025-524002-16-00Amyotrophic Lateral Sclerosis

Ferrer Internacional S.A., Prilenia Therapeutics B.V.

Nervous System Diseases

Belgium, Netherlands, Poland, France, Germany, Ireland, Italy, Sweden, Spain

20/04/2026

Phase III

J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.

2025-522855-25-00Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Ne…

DrugsEnfortumab Vedotin·Pembrolizumab

Eli Lilly & Co.

Neoplasms

Italy, Poland, Denmark, Czechia, France, Hungary, Germany, Netherlands, Spain

20/04/2026

Phase III

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

2025-522748-42-00Ovarian cancer

DrugsTopotecan·Doxorubicin·Gemcitabine·Paclitaxel

Incyte Corp.

Neoplasms

Ireland, Poland, France, Netherlands, Spain, Italy, Germany, Belgium

17/04/2026

Phase III

Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).

2025-523717-29-00HFpEF or HFmrEF and obesity

Novo Nordisk A/S

Cardiovascular Diseases

Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France

17/04/2026

Phase III

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

2025-523544-12-00Myelodysplastic neoplasms/syndromes (MDS)

Takeda Development Center Americas Inc.

Hemic and Lymphatic Diseases

France, Belgium, Germany, Italy, Bulgaria, Ireland, Lithuania, Norway, Romania, Hungary, Spain, Greece, Poland, Netherlands

17/04/2026

Phase III

The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia

2025-523096-34-00B-cell Acute Lymphoblastic Leukemia

Prinses Maxima Centrum voor Kinderoncologie B.V.

Hemic and Lymphatic Diseases

Spain, Germany, Netherlands

16/04/2026

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia

2025-521628-31-00Friedreich’s ataxia is the most common inherited ataxia in …

DrugNomlabofusp

Larimar Therapeutics Inc.

Nervous System Diseases

France

16/04/2026

Phase III

A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase III Therapeutic Superiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Diclofenac potassium + Thiocolchicoside to Diclofenac potassium (Cataflam®) in Patients with Acute Severe Low Back Pain.

2025-523153-33-00LOW BACK PAIN

DrugDiclofenac

Verisfield Single Member S.A.

Musculoskeletal Diseases

Cyprus, Greece

16/04/2026

Phase III

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

2025-523975-48-00Obesity

DrugBerobenatide

Metsera Inc.

Nutritional and Metabolic Diseases

Czechia, Bulgaria, Slovakia, Spain, Hungary, Germany, Romania, Poland

16/04/2026

Phase III

A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease

2024-518835-13-00Suspected Vascular Disease of supra-aortic (carotid/vertebr…

Guerbet, Bracco Imaging S.p.A.

Cardiovascular Diseases

Italy, France, Czechia, Hungary, Spain, Germany, Poland

15/04/2026

Phase III

Efficacy of Dexmedetomidine on Emergence Delirium in Children Undergoing Adenotonsillectomy: A Double-Blind Randomized Controlled Trial with Heart Rate Variability and Electroencephalography-Guided Anesthesia

2025-524086-24-00Emergence delirium

DrugDexmedetomidine

Akershus University Hospital

Nervous System Diseases

Norway

15/04/2026

Phase III

A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of fenfluramine hydrochloride in study participants with Rett syndrome

2025-523157-34-00Rett syndrome

UCB Biosciences Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Poland, France, Hungary, Belgium, Italy, Germany

15/04/2026

Phase III

PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma

2025-521571-30-00Young Adults and adults with R/R B-cell acute lymphoblastic…

DrugsImmunoglobulins·Levofloxacin·Azithromycin·Amoxicillin

Assistance Publique Hopitaux De Paris

Hemic and Lymphatic Diseases

France

13/04/2026

Phase III

Prevention of chronic headache with anti-CGRP antibody treatment in patients with idiopathic intracranial hypertension

2025-524822-16-00Idiopathic intracranial hypertension

Rigshospitalet

Nervous System Diseases

Denmark

13/04/2026

Phase III

A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures

2025-524038-24-00Focal Epilepsy

Praxis Precision Medicines Inc.

Nervous System Diseases

Poland, Germany, Czechia, Italy, Spain

10/04/2026

Phase III

LIBRETTO: Stimulan™ Local Antibiotic Delivery System Versus 4-Week Systemic Antibiotic Therapy for Diabetic Foot Osteomyelitis – A Prospective, Randomized, Controlled Trial

2025-524723-52-00Diabetic Foot Osteomyelitis

DrugsClindamycin·Ciprofloxacin·Levofloxacin·Metronidazole

Pirkanmaan hyvinvointialue

Bacterial Infections and Mycoses

Finland

10/04/2026

Phase III

Efficacy of intravenous dexamethasone in prolonging the duration of spinal anesthesia with chloroprocaine in knee arthroscopy.

2023-505247-39-00Knee arthroscopy

DrugDexamethasone

Centre Medico Chirurgical Ambroise Pare Hartmann

Anesthesia and Analgesia

France

08/04/2026

Phase III

FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial

2024-514964-24-00ulcerative colitis

DrugsFilgotinib·Ustekinumab·Vedolizumab·Infliximab

University Hospital Of Clermont-Ferrand

Digestive System Diseases

France

08/04/2026

Phase III

A randomized, Phase 3, open-label study to investigate pharmacokinetics, safety, and efficacy of subcutaneous compared to intravenous frexalimab in adult participants with multiple sclerosis.

2024-519304-28-00Multiple Sclerosis

Sanofi-Aventis Recherche & Developpement

Nervous System Diseases

Belgium, Spain, Italy

08/04/2026

Phase III

An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease

2025-522460-33-00Stargardt Disease

DrugTinlarebant

Belite Bio Inc.

Eye Diseases

Netherlands, France, Belgium

07/04/2026

Phase III

C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER

2025-523522-41-00Extensive-Stage Small Cell Lung Cancer

DrugsPF-08634404·Etoposide·Atezolizumab·Carboplatin

Pfizer Inc.

Neoplasms

France, Italy, Germany, Spain

07/04/2026

Phase III

Sevoflurane vs. propofol for general Anesthesia in patients with acute ischemic stroke treated with endoVascular treatmEnt (SAVE trial)

2025-523709-13-00Acute ischemic stroke

DrugPropofol

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Anesthesia and Analgesia

Spain

07/04/2026

Phase III

A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.

2025-521108-23-00Chronic Obstructive Pulmonary Disease

Glaxosmithkline Research & Development Limited

Respiratory Tract Diseases

Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania

07/04/2026

Phase III

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants with Diabetic Macular Edema (DME) (EYP-1901-303)

2025-523937-25-00Diabetic Macular Edema (DME)

Eyepoint Inc.

Eye Diseases

Germany, Poland, Slovakia

07/04/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 5)

2024-520444-42-00Overweight or obesity, and knee osteoarthritis

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Italy, Greece, Spain, Bulgaria, Denmark, Poland

07/04/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)

2024-520445-23-00Overweight or obesity, and knee osteoarthritis

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Greece, Poland, Spain, Bulgaria, Italy, Denmark

07/04/2026

Phase III

Multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with polyarticular-course juvenile idiopathic arthritis

2024-511593-70-00Polyarticular-course juvenile idiopathic arthritis

Alfasigma S.p.A.

Musculoskeletal Diseases

Spain, Bulgaria, France, Belgium, Germany, Greece, Italy, Poland, Hungary, Czechia

07/04/2026

Phase III

Evaluation of the efficacy and safety of bimekizumab (BZK) or adalimumab (ADA) in the treatment of anterior chest wall pain associated with active axial spondyloarthritis refractory to NSAIDs with hypothesis of superiority of bimekizumab. Randomized, open-label, in parallel arms, head to head trial (ThoracSPA)

2025-520632-42-00axial or predominantly axial SpA with or without psoriasis

DrugsBimekizumab·Adalimumab

Centre Hospitalier Universitaire Rouen

Musculoskeletal Diseases

France

03/04/2026

Phase III

A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases

2025-523017-28-00Locoregional Recurrence of Squamous Cell Carcinoma of the H…

Rakuten Medical Inc.

Neoplasms

Poland

03/04/2026

Phase III

Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, double-blind, placebo-controlled, phase 3 trial PEACH 2

2024-515663-59-00intracerebral haemorrhage

DrugLevetiracetam

Hospices Civils De Lyon

Nervous System Diseases

France

02/04/2026

Phase III

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH OVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER RANDOMIZED, CONTROLLED TRIAL (VESPER-4)

2025-523974-18-00Obesity

DrugBerobenatide

Metsera Inc.

Nutritional and Metabolic Diseases

Germany, Hungary, Slovakia, Poland, Spain, Czechia, Romania, Bulgaria

02/04/2026

Phase III

J3R-MC-YDAN - A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4) J3R-MC-YOA1: Intervention-Specific Appendix 1 (ISA1) for Eloralintide in Participants with Osteoarthritis Knee Pain J3R-MC-YOA2: Intervention-Specific Appendix 2 (ISA2) for Eloralintide in Participants with Osteoarthritis Knee Pain

2025-523768-19-00Osteoarthritis, Overweight or Obesity

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Denmark, Belgium, Germany, Czechia

02/04/2026

Phase III

AUTOP 2 : Screen-and-treat strategy for vaginal flora abnormalities by molecular biology in pregnant women at high risk of preterm birth: A Multicentre, Randomized Study

2023-509421-41-03Vaginal flora abnormalities, High risk preterm birth pregna…

DrugsAzithromycin·Metronidazole

Assistance Publique Hopitaux De Marseille

Bacterial Infections and Mycoses

France

01/04/2026

Phase III

A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)

2025-520479-25-00Symptomatic Venous Thromboembolism (VTE)

DrugsCenvacibart·Acetylsalicylic acid

Regeneron Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Greece, Italy, Spain

01/04/2026

Phase III

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

2025-522567-15-00Plaque Psoriasis

Takeda Development Center Americas Inc.

Skin and Connective Tissue Diseases

Spain, Poland, Germany, Italy

01/04/2026

Phase III

PembroLizumab Adjuvant in patients with early-stage Triple NEgaTive breast cancer with residual disease after neoadjuvant pembrolizumab plus chemotherapy – the multicenter, randomized phase III, pragmatic PLANET trial

2025-524229-41-00Triple negative breast cancer

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasms

Netherlands

01/04/2026

Phase III

Open Label Extension (OLE), multiple dose study to evaluate pharmacokinetics, safety, tolerability and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with juvenile idiopathic arthritis (JIA).

2025-523239-21-00Juvenile idiopathic arthritis

Alfasigma S.p.A.

Immune System Diseases

France, Germany, Poland, Belgium, Hungary, Spain, Czechia, Greece, Italy

01/04/2026

Phase III

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS trial)

2025-521936-12-00Adults with Type 2 Diabetes and/or Metabolic Syndrome on g…

NewAmsterdam Pharma B.V.

Cardiovascular Diseases

Czechia, Slovakia, Netherlands

31/03/2026

Phase III

Intranasal insulin for the prevention of delirium in ICU patients undergoing elective cardiac surgery: a randomized, double blind, placebo controlled pilot trial (INSPIRE)

2025-524680-21-00Delirium

Radboud universitair medisch centrum Stichting

Nervous System Diseases

Netherlands

30/03/2026

Phase III

2025-523938-10-00Diabetic Macular Edema (DME)

Eyepoint Inc.

Eye Diseases

Hungary, Czechia, Germany

30/03/2026

Phase III

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder

2025-523618-10-00Major Depressive Disorder

Xenon Pharmaceuticals Inc.

Mental Disorders

Finland, Poland, Romania, Slovakia, Spain, Germany

30/03/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)

2024-520442-36-00Overweight or obesity, and obstructive sleep apnoea not tre…

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Denmark, Poland, Spain, Germany

30/03/2026

Phase III

Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

2025-520466-22-00Advanced Platinum-resistant Epithelial Ovarian Cancer

AstraZeneca AB

Pathological Conditions, Signs and Symptoms

Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany

27/03/2026

Phase III

A Therapeutic Non-Inferiority, Randomized, Observer-blind, Active-comparator, Two-arm, Parallel Group, Multi-center Clinical Trial for Comparing the Efficacy and Tolerability of a Generic Fixed Dose Combination of Brimonidine Tartrate 2 mg/ml + Timolol 5 mg/ml Eye Drops versus Combigan® 2 mg/ml + 5 mg/ml Eye Drops in the Treatment of Intraocular Pressure in Patients with Open Angle Glaucoma or Ocular Hypertension

2025-523227-22-00Ocular Hypertension, Glaucoma

OmniVision GmbH

Eye Diseases

Greece

27/03/2026

Phase III

J3R-MC-YDAG - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes

2025-523657-34-00Obesity, Overweight

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Germany, Poland, Belgium

27/03/2026

Phase III

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

2024-519818-31-01Endometrial Cancer Advanced, Recurrent, Metastatic, or Prim…

DrugsDoxorubicin·Paclitaxel

Genmab A/S

Neoplasms

Poland, Denmark, Finland, Lithuania, France, Germany, Spain, Belgium, Greece, Norway, Italy

26/03/2026

Phase III

Clinical trial to evaluate the efficacy and safety of Depigoid DUO Grass-Mix/Olea (1000 DPP/mL + 1000 DPP/mL) compared with placebo in patients suffering from allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.

2025-521709-42-00Allergic rhinoconjunctivitis with or without asthma due to …

LETI Pharma S.L.U.

Immune System Diseases

Spain, Portugal

25/03/2026

Phase III

Clinical trial to evaluate the efficacy and safety of Depigoid Grass-Mix at 1000 DPP/mL and Depigoid FORTE Grass-Mix at 3000 DPP/mL compared with placebo in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma due to clinically relevant sensitisation to grass pollen.

2025-521736-10-00Allergic rhinoconjunctivitis with or without controlled ast…

LETI Pharma S.L.U.

Immune System Diseases

Portugal, Spain

25/03/2026

Phase III

IB1001-304: Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study

2025-523828-51-00CACNA1A Disorders

Intrabio Limited, IntraBio Inc

Nervous System Diseases

Italy, Germany, Austria, Greece

25/03/2026

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism (EMBARQ-COLDU and SD)

2025-522583-32-00Cold-Induced Urticaria and Symptomatic Dermographism

Celldex Therapeutics Inc.

Skin and Connective Tissue Diseases

Germany, Lithuania, Spain, Poland

25/03/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure (AMAZE 4)

2024-520443-16-00Overweight or obesity, and obstructive sleep apnoea treated…

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Poland, Spain, Germany

24/03/2026

Phase III

J3R-MC-YDAF - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Obesity or Overweight, and Type 2 Diabetes

2025-523658-15-00Obesity, Overweight

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Germany, Spain, Poland, Czechia, Slovakia

24/03/2026

Phase III

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction

2025-522475-28-00Pulmonary Hypertension (PH) with Heart Failure with preserv…

Tenax Therapeutics Inc.

Cardiovascular Diseases

France, Italy, Germany, Czechia, Austria, Poland, Hungary, Bulgaria, Spain

24/03/2026

Phase III

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

2025-523461-17-01LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Pfizer Inc.

Neoplasms

France, Italy, Hungary, Greece, Czechia, Spain, Poland, Germany

24/03/2026

Phase III

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).

2025-523085-24-00Biliary Tract Cancer

AstraZeneca AB

Neoplasms

Germany, Poland, Italy, Belgium, France, Netherlands, Spain

23/03/2026

Phase III

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema who are not Adequately Controlled With Topical Corticosteroids or When This Treatment is not Medically Advisable (LUMINE)

2025-522403-17-00Nummular Dermatitis

Almirall S.A.

Skin and Connective Tissue Diseases

Italy, Bulgaria, Spain, Germany, Poland, France

23/03/2026

Phase III

C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

2025-523521-18-00Metastatic Colorectal Cancer

DrugsPF-08634404·Calcium folinate·Fluorouracil·Oxaliplatin

Pfizer Inc.

Neoplasms

Spain, Belgium, France, Italy, Netherlands, Germany, Poland, Denmark

23/03/2026

Phase III

A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2

2024-513445-37-00previously untreated RT, irrespective of risk factors and d…

DrugsEpcoritamab·Pirtobrutinib·Prednisolone·Vincristine

University Of Cologne

Neoplasms

Austria, Germany, Denmark, Ireland, Netherlands, Italy

18/03/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency

2025-522051-26-00Acquired Angioedema due to C1 Inhibitor Deficiency

DrugDeucrictibant

Pharvaris Netherlands B.V.

Immune System Diseases

Hungary, Spain, Austria, Germany, Poland, Netherlands, France, Italy, Bulgaria

17/03/2026

Phase III

A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

2025-522191-86-00Focal segmental glomerulosclerosis

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Male Urogenital Diseases

Germany, Croatia, Poland, Sweden, Portugal, Netherlands, Italy, Denmark, Slovakia, Spain, Norway, Romania, Belgium, Greece, France

17/03/2026

Phase III

AchilleS tendinoPathy treated with cortIcosteRoid injEctions.

2025-524057-13-00Achilles tendinopathy

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Musculoskeletal Diseases

Netherlands

16/03/2026

Phase III

A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)

2025-522878-36-00Chronic Spontaneous Urticaria

Celldex Therapeutics Inc.

Skin and Connective Tissue Diseases

Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland

16/03/2026

Phase III

Prestige 2- RimegePant in RElation to obeSiTy in miGainE

2025-521475-31-00Migraine

Konvent Der Barmherzigen Brueder

Nervous System Diseases

Austria

13/03/2026

Phase III

“Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicentre Randomized Controlled Trial” THE IVT ALL IN TRIAL

2024-520414-21-00Adult patients with a LVOS with large core within 9 hours o…

DrugTenecteplase

Assistance Publique Hopitaux De Paris

Nervous System Diseases

France

12/03/2026

Phase III

An open label, pharmacokinetic and safety study of Combogesic® IV in pediatric patients with acute pain.

2025-524431-39-00Acute pain

Aft Pharmaceuticals Limited

Anesthesia and Analgesia

Hungary

12/03/2026

Phase III

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

2024-517943-29-00Pulmonary Hypertension associated with interstitial lung di…

DrugTreprostinil

Liquidia Technologies Inc.

Respiratory Tract Diseases

Latvia, Germany, Italy, Czechia, France, Belgium, Portugal, Poland, Austria, Spain

11/03/2026

Phase III

TENACITY – A Phase III, prospective, randomized, open-label, blinded endpoint assessment (PROBE) to assess efficacy and safety of i.v. tenecteplase vs standard of care in patients with acute ischemic stroke (including wake-up stroke), last known well >4.5 h with imaging evidence of salvageable ischemic tissue

2025-522542-40-00Acute Ischemic Stroke

Boehringer Ingelheim International GmbH

Cardiovascular Diseases

Greece, Norway, Hungary, Romania, Spain, Bulgaria

11/03/2026

Phase III

Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)

2025-522484-15-00ER+/HER2- early breast cancer

WSG Women's Cancer Study Group GmbH

Neoplasms

Germany, Spain, Austria

11/03/2026

Phase III

Prehospital pulse-dose glucocorticoid in patients with STEMI – the PULSE-MI 2 trial

2025-524320-21-00ST-segment Elevation Myocardial Infarction

Rigshospitalet

Cardiovascular Diseases

Denmark

11/03/2026

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,788 trial records at the last sync on 07 Nov 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 789 of those trials that match the filters currently applied.

How many clinical trials does CTIS hold?

CTIS held 12,788 trial records at the last sync. Of the 2,557 most recently authorised trials shown in this register, 789 are Phase III, and 789 match the filters currently applied. Trials are counted by authorisation, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase, 789 trials
Phase	Trials	Share
Phase III	789	100%

Most active sponsors

Lead sponsors with the most trials
Lead sponsor	Trials
AstraZeneca AB	31
Assistance Publique Hopitaux De Paris	26
Novo Nordisk A/S	24
Bristol-Myers Squibb Services Unlimited Company	22
Eli Lilly & Co.	21
Pfizer Inc.	18
Merck Sharp & Dohme LLC	16
Sanofi-Aventis Recherche & Developpement	16
Janssen Cilag International	14
Glaxosmithkline Research & Development Limited	13

Member states with the most trials

Member states by number of trials with a site there
Member state	Trials
Spain	468
France	440
Germany	420
Italy	392
Poland	356
Belgium	234
Netherlands	233
Czechia	213
Hungary	171
Greece	166

→

Browse trials by member state

Spain (1074) France (933) Germany (893) Italy (777) Poland (614) Netherlands (544) Belgium (453) Czechia (340) Denmark (316) Hungary (255) Greece (237) Bulgaria (217) Romania (217) Austria (216) Sweden (200)

→

Browse trials by condition

Advanced solid tumors (23) Atopic Dermatitis (19) Non-Small Cell Lung Cancer (15) Obesity (14) Parkinson’s disease (14) Multiple sclerosis (13) Rheumatoid arthritis (13) Ulcerative Colitis (12) Breast Cancer (11) Prostate Cancer (10)

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.